



Date: March 21, 2023

To

Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai – 400001

Scrip Code: 526169

Dear Sir/Madam,

Sub: Notice of Postal Ballot and remote e-voting information in newspapers.

Please find enclosed copy of the notice of Postal Ballot and remote E-voting information published in Newspapers dated March 21, 2023.

This is for your information and records.

Thanking you,

Yours truly,

For **Multibase India Limited**

PARMY
SHAILESH
KAMANI

Digitally signed by
PARMY SHAILESH
KAMANI
Date: 2023.03.21
17:32:22 +05'30'

Parmy Kamani
Company Secretary and Compliance Officer
Encl.: As above

Multibase India limited

ભાજપના MLA અને IT સેલના કાર્યકર વચ્ચે ડબ્બો

રાજકોટ, તા. ૨૦
રાજકોટ શહેર ભાજપમાં આંતરિક વિવાદ ચરમસીમાએ પહોંચ્યો છે. ધારાસભ્ય અને IT સેલના કાર્યકર વચ્ચે આંતરિક બટાગાચાલી રહી છે તેવું ધ્યાને આવ્યું છે. ધારાસભ્ય દર્શિતા શાહને IT સેલ મહત્વ ન આપી તે હોવાનો આરોપ લગાવવામાં

આવી રહ્યો છે. દર્શિતા શાહ અને IT સેલના અતુલ નયવાણીનો ઓડિયો વાયરલ થયો છે. એક ઓડિયો વાયરલ થઈ રહ્યો છે જે ઓડિયોમાં દર્શિતા શાહના IT સેલ પર ગંભીર આરોપ છે. ધારાસભ્યના કોટા સોશિયલ મીડિયામાં પોસ્ટ ન કરાયાનો આરોપ લગાવવામાં આવી રહ્યો છે. દર્શિતા શાહ જણાવી રહ્યાં છે કે, IT સેલ માટે કોટા સોશિયલ મીડિયામાં મુકવું નથી. જે સમગ્ર મામલે દર્શિતા શાહ અને તેના પતિના IT સેલના કાર્યકરોને ખમવ્યા છે. વોર્ડ નંબર ૨ના ભાજપના સુપ્રમમાંથી IT સેલના કાર્યકરોને કહાયા છે. જે ઓડિયોમાં આઈટી સેલના કાર્યકર્તા તેમજ ધારાસભ્ય દર્શિતા શાહ કોટા મુકવા સામે સામે બોલાચાલી કરી રહ્યાં છે, જે

ઓડિયોમાં દર્શિતા શાહ જણાવી રહ્યાં છે કે, મારા કોટા વોર્ડ નંબર ૨માં કેમ નથી મુકતા અને આગળ આ ભાજપની ફરિયાદ કરીશ તેમ જણાવી રહ્યાં છે જ્યારે કાર્યકર્તા કહે છે કે, મને તેમાં જોડાઈ કરી દેવામાં આવે છે. કાર્યકર્તા એતુલ નાથવાણીએ કહ્યું કે, કરી નાંખો મને કાંઈ વાંધો નથી.

સુરત ૧૦૮ એમ્બ્યુલન્સની પ્રસંશનીયા કામગીરી ૧૦૮ દ્વારા છેલ્લા ૫ વર્ષમાં કરાવી ૫૫૩૯ મહિલાની પ્રસૂતિ વર્ષ ૨૦૧૮થી સુરતમાં ૨૧૭,૨૬૪ કોલ મળ્યા

સુરત, તા. ૨૦
૧૦૮ ઈમરજન્સી સેવા લોકો માટે આશીર્વાદ સમાન બની છે. ત્યારે સગર્ભા મહિલાઓ, અકસ્માત કે અન્ય કોઈ પણ ઈમરજન્સી સારવાર માટે ૧૦૮ એમ્બ્યુલન્સ વરદાન બની છે. ત્યારે ૧૦૮ ઈમરજન્સી સેવાનાં કારણે કેટલાય લોકોનો જીવ બચી જવા પામ્યો છે. સુરતમાં ૧૦૮ એમ્બ્યુલન્સમાં છેલ્લા ૫ વર્ષમાં ૫૫૩૯ મહિલાઓની પ્રસૂતિ કરવામાં આવી છે.

સુરતમાં ૧૦૮ એમ્બ્યુલન્સને ૨ લાખ ૧૭ હજાર ૨૬૪ કોલ મળ્યા છે. ત્યારે ૫૫૩૯ કોલ પર તરિત ડિલિવરી કરાઈ છે. આ બાબતે સુરત જિલ્લામાં ૧૦૮ માં પ્રોગ્રામ અધિકારી તરીકે ફરજ બજાવતા જીતેન્દ્રભાઈએ જણાવ્યું હતું કે ૧૦૮ ની ટીમે અત્યારે સુધી ૫૫૩૯ ડિલિવરી કરાવી છે. ત્યારે

ઘણી ડિલિવરી એમ્બ્યુલન્સમાં કરાવવામાં આવી છે. ત્યારે લોકોને અપિલ છે કે જ્યારે પણ સુવાવડનો દુ:ખાવો થાય ત્યારે તુરંત જ ૧૦૮ ને જાણ કરવી. જેથી ડિલિવરી યતના સ્થળ પર કરાવવાની ફરજ ન પડે. અને એક્સિપિટલમાં ઈકરની દેખરેખ હેઠળ ડિલિવરી કરાવી શકાય.

સુરતની નવયુગ કોલેજ દ્વારા સેનામાં ભરતી થવા માટે શરૂ થશે ટ્રેનિંગ આપતા કોર્ષ

સુરત, તા. ૨૦: સુરત શહેરમાં આવેલી નવયુગ કોલેજ દ્વારા નવા વર્ષથી અનેક નવા કોર્ષની શરૂઆત કરવામાં આવી રહી છે. ખાસ કરીને, જે યુવાનોને અગ્નિવીર બનવાની ઈચ્છા છે તેમના માટે આ કોર્ષ ખુબ જ અગત્યનો છે. કારણ કે, નવા કોર્ષમાં અગ્નિવીર તરીકે ભરતી થવા માટેની જરૂરી ટ્રેનિંગ આપવામાં આવશે. નવયુગ કોલેજે વીર નર્મદ દક્ષિણ યુનિવર્સિટી પાસે આ કોર્ષ શરૂ કરવાની મંજૂરી માંગી હતી. ત્યારે યુનિવર્સિટીએ તેને પરવાનગી આપી

નવયુગ કોલેજ પણ ભારતની પ્રથમ કોલેજ હશે કે જ્યાં આપવામાં આવશે સેનાની ટ્રેનિંગ હતી. વીર નર્મદ દક્ષિણ ગુજરાત યુનિવર્સિટી દેશની પ્રથમ એવી યુનિવર્સિટી બનશે કે જે આ પ્રકારનો કોર્ષ શરૂ કરશે અને નવયુગ કોલેજ પણ ભારતની પ્રથમ કોલેજ હશે કે જ્યાં સેનાની ટ્રેનિંગ આપવામાં આવશે. આ મામલે કોલેજના પ્રિન્સિપાલે જણાવ્યું હતું કે, 'નવયુગ કોલેજમાં આ કોર્ષની શરૂઆત કરવામાં આવશે. ૪૫ કલાકનો આ કોર્ષ હશે. તેમાં વિદ્યાર્થીઓને પ્રેક્ટિકલ અને

થિયોરેટિકલ એમ બંને મોડમાં ભણાવવામાં આવશે. વિદ્યાર્થીઓને ક્લાસરૂમમાં થીપરી અને ડ્રાઉન્ટમાં પ્રેક્ટિકલ કરાવવામાં આવશે. અહીં વિદ્યાર્થીઓને દરરોજ એક કલાક ત્રીસ મિનિટ સુધી ટ્રેનિંગ આપવામાં આવશે. આ વિદ્યાર્થીઓને અગ્નિવીર માટે તૈયાર કરવામાં આવશે. વિદ્યાર્થીઓ હવે તૈયાર થઈને સેનામાં જઈ દેશની સેવા કરી શકશે. સુરતવાસીઓમાં પણ ભારે ઉત્સાહ જોવા

સુરતમાં ૧૦૮ એમ્બ્યુલન્સ દ્વારા પ્રસંશનીયા કામગીરી કરવામાં આવી છે. સગર્ભા મહિલાઓ માટે ઈમરજન્સી ૧૦૮ એમ્બ્યુલન્સ વરદાન બની છે. છેલ્લા પાંચ વર્ષમાં ૫ હજાર ૫૩૯ મહિલાઓની પ્રસૂતિ ૧૦૮ એમ્બ્યુલન્સ દ્વારા કરાવવામાં આવી છે. જેમાં વર્ષ ૨૦૧૮ થી

બારડોલી:વાંકાનેર માટે આશીર્વાદરૂપ બન્યું 'અમૃત સરોવર' વાંકાનેર ગામના ખેડૂતો માટે અમૃત સરોવરનું જળ ખેતી માટે અમૃત સમાન બન્યું છે:ભાવિકભાઈ પટેલ

સુરત, તા. ૨૦: ૪ એપ્રિલ, ૨૦૨૨ ના રોજ પંચાયતી રાજ દિવસ નિમિત્તે વડાપ્રધાનશ્રી નરેન્દ્ર મોદીએ દેશમાં ૫૦ હજાર અમૃત સરોવરોનું નિર્માણ કરવાનું રચનાત્મક સૂચન કર્યું હતું. જેને અનુસરીને રાજ્યના દરેક જિલ્લામાં ૭૫ અમૃત સરોવર બનાવવાનું રાજ્ય સરકારે આયોજન હાથ ધર્યું છે. સાથેસાથ રાજ્યભરમાં ભૂગર્ભ જળનું સ્તર ઊંચુ આવે અને વરસાદી પાણીનો વધુ સંગ્રહ થાય તેવા હેતુથી આ વર્ષે પણ રાજ્યવ્યાપી 'સુશ્રાવ્યસુશ્રાવ્ય જળ અભિયાન' પણ શરૂ થઈ ચૂક્યું છે, ત્યારે સુરત જિલ્લાના બારડોલી તાલુકાના વાંકાનેર ગામમાં

અમૃત સરોવરના નિર્માણનું કાર્ય પૂર્ણ થતા ખેડૂતોમાં હરખની હલી ઉઠી છે. સુશ્રાવ્ય સુશ્રાવ્ય યોજના થકી બારડોલીના વાંકાનેર ગામમાં અમૃત સરોવરનું જળ ખેતી માટે અમૃત સમાન બનશે એવી ભાવના વ્યક્ત કરતા વાંકાનેરના ખેતુ ભાવિકભાઈ પટેલ જણાવે છે કે, અમે વર્ષોથી વરસાદ આધારિત ખેતી કરીએ છીએ, એટલે સ્વાભાવિક છે કે અમારા માટે જળનો એક માત્ર સ્ત્રોત વરસાદ જ હોય. પરંતુ સરકારની અમૃત સરોવર યોજના થકી ગામના ખોદકામ કરી તળાવને ઊંડું કરવામાં આવ્યું છે. જેનાથી હવે પાણીના

સંગ્રહમાં વધારો થયો છે. આ તળાવના પુન:નિર્માણથી ગામના મારા જેવા એનક ખેડૂતોને પાણી સમસ્યાનું નિરાકરણ થયું છે. હવે અમે વરસાદના બરોસે નહીં ખેતી રહીશું. તળાવના નિર્માણ થકી જલસતર ઉપર આવતા ખેતરોમાં ૨૪ કલાક પાણીની સુવિધા ઉપલબ્ધ થઈ છે. ભાવિકભાઈ કહે છે કે, પહેલા ગામમાં તળાવ નાનું હતું, અને નહેરુ પાણી પણ ઉપલબ્ધ ન હતું. પણ સરકારે 'સુશ્રાવ્ય સુશ્રાવ્ય યોજના' હેઠળ જળસંચય અભિયાનને વેગ આપ્યો જેના સારા પરિણામો મળી રહ્યા છે. અમારા ગામમાં અમૃત સરોવર બનાવ

તળાવનો વિસ્તાર વધ્યો છે, જેમાં વધુ પ્રમાણમાં વરસાદી પાણીનો સંગ્રહ થતા સિંચાઈ અને રોજબરોજના વપરાશ માટે આ પાણીનો વ્યાપક ઉપયોગ થઈ રહ્યો છે. આજે ગામમાં 'સિંચાઈ સેતુ સમૃદ્ધિ' આવી છે એમ કહીએ તો ખોટું નથી. અમે ગ્રામજનો તથા

આસપાસ લીમડો, પીપ્પાળો, વડ જેવા ઘડાંદાર વૃક્ષો વાવીને તેની સુંદરતામાં વધારો થાય એ દિશામાં કાર્ય કરી રહ્યા છીએ.

યેમ્બરની પબ્લીક હેલ્થ કમિટી અને લેડીઝ વીંગ દ્વારા 'એન્ટી-એજિંગ એન્ડ રિજનરેટીવ મેડીસીન' વિષે જનજાગૃતિ સત્ર યોજાયું જર્મની સ્થિત નિષ્ણાત ડૉ. શમ્સ શેકે 'ન્યુ એજ કોન્સેપ્ટ' ઉપર એન્ટિ-એજિંગ માટે ઉપયોગી એવા દર્સ જુદા-જુદા પગલાં તથા જર્મન ટેકનોલોજી દ્વારા શોધાયેલી વિવિધ થેરપી વિષે આપી વિસ્તૃત સમજણ



સુરત, પી સધર્ન ગુજરાત યેમ્બર ઓફ કોમર્સ એન્ડ ઈન્ડસ્ટ્રીની પબ્લીક હેલ્થ કમિટી અને લેડીઝ વીંગ દ્વારા શનિવાર, તા. ૧૮ માર્ચ ૨૦૨૩ ના રોજ સાંજે ૬:૦૦ કલાકે, સરસાણા સ્થિત સંહતિ બિલ્ડિંગમાં બીજા માળે પિરિયાટ્રિક હોલમાં 'એન્ટી-એજિંગ એન્ડ રિજનરેટીવ મેડીસીન' વિષય પર જનજાગૃતિ સત્રનું આયોજન કરવામાં આવ્યું હતું. જેમાં જર્મની સ્થિત નિષ્ણાત ડૉ. શમ્સ શેકે ન્યુ એજ કોન્સેપ્ટ ઉપર એન્ટિ-એજિંગ માટે ઉપયોગી એવા દર્સ જુદા-જુદા પગલાં તથા જર્મન ટેકનોલોજી દ્વારા શોધાયેલી વિવિધ થેરપી વિષે વિસ્તૃત સમજણ આપી હતી.

ગુપ્તા ચેરમેન વિવિધ સવાલો ડૉ. શમ્સ શેકે જવાબો આપ્યા હતા અને વક્તાનો ત્યારબાદ સત્રનું સમાપન થયું.

પશ્ચિમ રેલવે સલાય, ઇન્સ્ટોલેશન, ટેસ્ટિંગ કમિશનિંગ વર્કસ સિનિસ્ટર ડિવિઝનલ સિગ્નલ એન્ડ ટેલિકોમ એન્જિનિયર (ઉપર), બીએ માળ, ડિવિઝનલ હેલ્થ મેનેજર ઓફિસ, મુંબઈ સેન્ટ્રલ, મુંબઈ-૪૦૦ ૦૦૮. ટેલેકોમ નોંધ નંબર: WRR-MMCT-SnT-STTD-11-2023 તારીખ-૨૦/૦૩/૨૦૨૩ આમંત્રિત કરે છે. કાર્ય અને સ્થાન: મુંબઈ ડિવિઝનની અમૃત ભારત સ્ટેશન સોજના ડેટાન સિગ્નલ, બેટાન, વાડોલી, જમવાનેર, ઘાસગાંધી સ્ટેશનમાં ઇન્સ્ટોલેશન પેસેન્સર ઇન્ફોર્મેશન સિસ્ટમ (IPIS)નું સપ્લાય, ઇન્સ્ટોલેશન, પરીક્ષણ. કમ્પાની સાથે કોન્ટ્રાક્ટ નંબર: ૬૫૪૩૯૧૭૯૩. ૬૬. ઈમેલ: ૬૬૨૨૦૦૦/પાસ ઓફિસ જ્યાં ઈ-ટેન્ડર ખુલે છે: ઉપર જણાવેલ સમગ્રનું. ઈ-ટેન્ડરનો પ્રકાર: ઓપન ઇ-ટેન્ડર. ઈ-ટેન્ડર દસ્તાવેજો સળમિટ કરવા માટે સમય અને તારીખ: ૧૧.૦૪.૨૦૨૩ ના રોજ ૧૬.૦૦ કલાકે. ૧૧.૦૪.૨૦૨૩ ના રોજ ૧૬.૩૦ કલાકે ઈ-ટેન્ડર ખોલવાનો સમય અને તારીખ. ટેન્ડર વેબ સાઈટ: <http://www.irps.gov.in> પર જઈ શકાય છે. ૦૯૭૦

એજિંગ માટે ઉપયોગી એવા દર્સ જુદા-જુદા પગલાં વિષે માહિતી આપી હતી. જેમાં મેક્રો ન્યુટ્રિશન, ઓર્થો મોલ્યુક્યુલર ન્યુટ્રિશન, પીએચ/એસિડ બેલેન્સ, ઈમ્યુન સિસ્ટમ સપોર્ટ, આયો આઈડી-૨૦૨૩ હોર્મોન રિપ્લેસમેન્ટ, પેપ્ટાઈડ થેરપી, રેગ્યુલર ડિટોક્સીફિકેશન, ઓક્સિજન થેરપી અને ઓક્સીજન થેરપીનો સમાવેશ થાય છે. તજાવમાંથી મુક્ત થવા માટે પર્સનલાઈઝ્ડ એક્સરસાઈઝ પ્રોગ્રામ પણ વિકસાવવામાં આવ્યો છે, જેના વિષે તેમણે સવિસ્તર માહિતી આપી હતી. આ ઉપરાંત ટીચરુ ઓર્થોપીડિયોલોજી વિષે પણ વિસ્તૃત જાણકારી આપી હતી. યેમ્બર ઓફ કોમર્સના પ્રમુખ હિમાંશુ બોડાવાલાએ સ્વાગત પ્રવચન કર્યું હતું. યેમ્બરના ઉપ પ્રમુખ રમેશ વઘાસિયા, તત્કાલિન ભૂતપૂર્વ પ્રમુખ આશીષ ગુજરાતી તથા માનદ મંત્રી ખાવેશ ટેલર અને માનદ બજાનથી ખાવેશ ગઢીયા તેમજ ગુપ ચેરમેન ડૉ. બંદના ભટ્ટાચાર્ય અને લેડીઝ વીંગના ચેરપર્સન જ્યોત્સના ગુજરાતી સત્રમાં ઉપસ્થિત રહ્યાં હતાં. યેમ્બરના ગુપ ચેરમેન નિખિલ મદ્રાસીએ સમગ્ર સત્રનું સંવાલન કર્યું હતું. લુથરા

સુરત, પી સધર્ન ગુજરાત યેમ્બર ઓફ કોમર્સ એન્ડ ઈન્ડસ્ટ્રીની પબ્લીક હેલ્થ કમિટી અને લેડીઝ વીંગ દ્વારા શનિવાર, તા. ૧૮ માર્ચ ૨૦૨૩ ના રોજ સાંજે ૬:૦૦ કલાકે, સરસાણા સ્થિત સંહતિ બિલ્ડિંગમાં બીજા માળે પિરિયાટ્રિક હોલમાં 'એન્ટી-એજિંગ એન્ડ રિજનરેટીવ મેડીસીન' વિષય પર જનજાગૃતિ સત્રનું આયોજન કરવામાં આવ્યું હતું. જેમાં જર્મની સ્થિત નિષ્ણાત ડૉ. શમ્સ શેકે ન્યુ એજ કોન્સેપ્ટ ઉપર એન્ટિ-એજિંગ માટે ઉપયોગી એવા દર્સ જુદા-જુદા પગલાં તથા જર્મન ટેકનોલોજી દ્વારા શોધાયેલી વિવિધ થેરપી વિષે વિસ્તૃત સમજણ આપી હતી.

એજિંગ માટે ઉપયોગી એવા દર્સ જુદા-જુદા પગલાં વિષે માહિતી આપી હતી. જેમાં મેક્રો ન્યુટ્રિશન, ઓર્થો મોલ્યુક્યુલર ન્યુટ્રિશન, પીએચ/એસિડ બેલેન્સ, ઈમ્યુન સિસ્ટમ સપોર્ટ, આયો આઈડી-૨૦૨૩ હોર્મોન રિપ્લેસમેન્ટ, પેપ્ટાઈડ થેરપી, રેગ્યુલર ડિટોક્સીફિકેશન, ઓક્સિજન થેરપી અને ઓક્સીજન થેરપીનો સમાવેશ થાય છે. તજાવમાંથી મુક્ત થવા માટે પર્સનલાઈઝ્ડ એક્સરસાઈઝ પ્રોગ્રામ પણ વિકસાવવામાં આવ્યો છે, જેના વિષે તેમણે સવિસ્તર માહિતી આપી હતી. આ ઉપરાંત ટીચરુ ઓર્થોપીડિયોલોજી વિષે પણ વિસ્તૃત જાણકારી આપી હતી. યેમ્બર ઓફ કોમર્સના પ્રમુખ હિમાંશુ બોડાવાલાએ સ્વાગત પ્રવચન કર્યું હતું. યેમ્બરના ઉપ પ્રમુખ રમેશ વઘાસિયા, તત્કાલિન ભૂતપૂર્વ પ્રમુખ આશીષ ગુજરાતી તથા માનદ મંત્રી ખાવેશ ટેલર અને માનદ બજાનથી ખાવેશ ગઢીયા તેમજ ગુપ ચેરમેન ડૉ. બંદના ભટ્ટાચાર્ય અને લેડીઝ વીંગના ચેરપર્સન જ્યોત્સના ગુજરાતી સત્રમાં ઉપસ્થિત રહ્યાં હતાં. યેમ્બરના ગુપ ચેરમેન નિખિલ મદ્રાસીએ સમગ્ર સત્રનું સંવાલન કર્યું હતું. લુથરા

પશ્ચિમ રેલવે સલાય, ઇન્સ્ટોલેશન, ટેસ્ટિંગ કમિશનિંગ વર્કસ સિનિસ્ટર ડિવિઝનલ સિગ્નલ એન્ડ ટેલિકોમ એન્જિનિયર (ઉપર), બીએ માળ, ડિવિઝનલ હેલ્થ મેનેજર ઓફિસ, મુંબઈ સેન્ટ્રલ, મુંબઈ-૪૦૦ ૦૦૮. ટેલેકોમ નોંધ નંબર: WRR-MMCT-SnT-STTD-11-2023 તારીખ-૨૦/૦૩/૨૦૨૩ આમંત્રિત કરે છે. કાર્ય અને સ્થાન: મુંબઈ ડિવિઝનની અમૃત ભારત સ્ટેશન સોજના ડેટાન સિગ્નલ, બેટાન, વાડોલી, જમવાનેર, ઘાસગાંધી સ્ટેશનમાં ઇન્સ્ટોલેશન પેસેન્સર ઇન્ફોર્મેશન સિસ્ટમ (IPIS)નું સપ્લાય, ઇન્સ્ટોલેશન, પરીક્ષણ. કમ્પાની સાથે કોન્ટ્રાક્ટ નંબર: ૬૫૪૩૯૧૭૯૩. ૬૬. ઈમેલ: ૬૬૨૨૦૦૦/પાસ ઓફિસ જ્યાં ઈ-ટેન્ડર ખુલે છે: ઉપર જણાવેલ સમગ્રનું. ઈ-ટેન્ડરનો પ્રકાર: ઓપન ઇ-ટેન્ડર. ઈ-ટેન્ડર દસ્તાવેજો સળમિટ કરવા માટે સમય અને તારીખ: ૧૧.૦૪.૨૦૨૩ ના રોજ ૧૬.૦૦ કલાકે. ૧૧.૦૪.૨૦૨૩ ના રોજ ૧૬.૩૦ કલાકે ઈ-ટેન્ડર ખોલવાનો સમય અને તારીખ. ટેન્ડર વેબ સાઈટ: <http://www.irps.gov.in> પર જઈ શકાય છે. ૦૯૭૦

પશ્ચિમ રેલવે સલાય, ઇન્સ્ટોલેશન, ટેસ્ટિંગ કમિશનિંગ વર્કસ સિનિસ્ટર ડિવિઝનલ સિગ્નલ એન્ડ ટેલિકોમ એન્જિનિયર (ઉપર), બીએ માળ, ડિવિઝનલ હેલ્થ મેનેજર ઓફિસ, મુંબઈ સેન્ટ્રલ, મુંબઈ-૪૦૦ ૦૦૮. ટેલેકોમ નોંધ નંબર: WRR-MMCT-SnT-STTD-11-2023 તારીખ-૨૦/૦૩/૨૦૨૩ આમંત્રિત કરે છે. કાર્ય અને સ્થાન: મુંબઈ ડિવિઝનની અમૃત ભારત સ્ટેશન સોજના ડેટાન સિગ્નલ, બેટાન, વાડોલી, જમવાનેર, ઘાસગાંધી સ્ટેશનમાં ઇન્સ્ટોલેશન પેસેન્સર ઇન્ફોર્મેશન સિસ્ટમ (IPIS)નું સપ્લાય, ઇન્સ્ટોલેશન, પરીક્ષણ. કમ્પાની સાથે કોન્ટ્રાક્ટ નંબર: ૬૫૪૩૯૧૭૯૩. ૬૬. ઈમેલ: ૬૬૨૨૦૦૦/પાસ ઓફિસ જ્યાં ઈ-ટેન્ડર ખુલે છે: ઉપર જણાવેલ સમગ્રનું. ઈ-ટેન્ડરનો પ્રકાર: ઓપન ઇ-ટેન્ડર. ઈ-ટેન્ડર દસ્તાવેજો સળમિટ કરવા માટે સમય અને તારીખ: ૧૧.૦૪.૨૦૨૩ ના રોજ ૧૬.૦૦ કલાકે. ૧૧.૦૪.૨૦૨૩ ના રોજ ૧૬.૩૦ કલાકે ઈ-ટેન્ડર ખોલવાનો સમય અને તારીખ. ટેન્ડર વેબ સાઈટ: <http://www.irps.gov.in> પર જઈ શકાય છે. ૦૯૭૦

અહેર નોટીસ
મે.પારડીના એડીશનલ સીવિલ જજ અને જ્યુડી.મેટુ.
ફ.ક.સાહેબની હોર્ટમાં, મુ.પારડી, જિ.વલસાડ
પરવુકા અસ્ટુ નં-૧૧/૨૦૨૩
મુકાદ ઠા.૨૪/૦૩/૨૦૨૩
અવગણ: કોલેક્ટર ઈમરજન્સી કાર્યાલય
રો.૨૦૧, સોલો કોલેક્ટર ડિવિઝન, બી-૨૦૧, લોક ૨૦૧૨ કોલેક્ટર, નોબલ, સાને (ટે.ક) ૪૦૦ ૬૦૨
મો.૯૦૦૦૮૦૦૩૩૧ (વ.શી.સેલ.૨૫૨.૫૬૦૨)
સામવાળા: વીક એડિટરશ્રી, પારડી નગરપાલિકા, ઠા.પારડી, જિ.વલસાડ
સાચી તમામ સંબંધિત પક્ષકારોને આ અહેર નોટીસથી જાણ કરવામાં આવે છે કે, આ કમના અવગણ કોલેક્ટર ઈમરજન્સી કાર્યાલયને આરોગી સહાયતા ડિવિઝન નંબર ૧૦૧ પિલા નામે હવમગી માવકુલ કાર્યાલય મુકાદ તારીખ ૦૯/૦૩/૨૦૨૩ના રોજ મેનેજર-કોલેક્ટર પારડી, ઠા.પારડી, જિ.વલસાડમાં સરકારી ઈન્સ્ટોલેશન થયેલ છે. જે મરહુમી નોંધ સરકારી હકને લઈ લઈ. મરહુમે તેમના મિલાન મરહુમ ઘણાની સરકારી કમલકાર તથા સમગ્ર કમલકાર રહી જરૂરી હોય માટે લોક ઓફિસરશ્રી, પારડી નગરપાલિકા, ઠા.પારડી, જિ.વલસાડની કચેરીને કરવાય રા ર ઈમેલ સરકારી મેમોરી ટેલર છે. આવી મરહુમની સહાય સામે કોઈપણ ઈતમને કોઈ વંધી વા હકલત છે, તો તેમને આ અહેર નોટીસ પ્રસિદ્ધ થયેથી, આરોગી સહાયતા ડિવિઝન મુનવાલ વડીલ મારકેટ હાવર રહેશે. જો તેમ કમમાં કહુલ કરશે, તો અવગણને સંબંધી એમ હુકમ કરવામાં આવશે. જેની નોંધ લેશે. આજ રોજ ઠા.૧૮/૦૩/૨૦૨૩ ના રોજ મારી રહી તમા કોર્ટને કિલ્લો કરીને આવશે.

અહેર નોટીસ
પ્રાંત અધિકારી અને સબ ડીવીઝનલ મેજસ્ટ્રેટ, પારડીની હોર્ટમાં
નં.૧૧/૨૦૨૩/૦૩/૨૦૨૩
અવગણ: મહાનિયા સુભાષી પટેલ
રો.૨૦૧, સોલો કોલેક્ટર ડિવિઝન (વ.શી.સેલ.૨૫૨.૫૬૦૨)
સામવાળા: વીક એડિટરશ્રી નગરપાલિકા, ઠા.પારડી, જિ.વલસાડ
જન્મ/મરણ અધિકાર-૧૯૭૮ની ૦૬-૧૩(૩) અવધે જન્મલી નોંધ કરાવવા માટેની હુકમ મેળવવા માટેની અવગણ અવધે નોટીસ.
આવી અવગણ-અવગણ ઈતમને જણાવવામાં છે, અવગણને જન્મ-મરણ અધિકાર દેહન અવગણ કરે છે કે, અવગણની મહાનિયા સુભાષી પટેલ, રો.૨૦૧, સોલો કોલેક્ટર ડિવિઝન, ઠા.પારડી, જિ.વલસાડમાં તેમની પુત્રી પટેલ સુભાષી પટેલની જન્મ તા.૧૭/૦૬/૧૯૭૮ના રોજ મેનેજર-કોલેક્ટર ઠા.પારડી મુકાદ રહેવાયા છે તેવું છે. તેમજ જન્મની નોંધથી જે તે વખતે કમલકારી સહાય કોઈ વ્યક્ત અને સરકારી કમલકારી રહી ગયેલ છે. જેથી તેમની કોર્ટમાં અવગણ અવગણ કરેલ છે. અવગણની નોંધથી અવગણ કરીને વંધી વા હકલત કરેલ છે, તો પોરે અવગણ વડીલ મારકેટ હાવર હાવર પ્રસિદ્ધ થવા તારીખથી ૩૦ દિવસની અંદર સબ ડીવીઝનલ મેજસ્ટ્રેટ અને પ્રાંત અધિકારી પારડી, અને કચેરી પારડી, જિ.વલસાડની કચેરીને વાંચા રજુ કરવામાં રહેશે. જો વાંચી નહીં આવે, તો વંધી નથી તેમ આવી અવગણની કમલકારી કરવામાં આવશે. જેની તમામ અવગણ-અવગણ ઈતમને નોંધ લેવી.
આજ રોજ ઠા.૨૪/૦૩/૨૦૨૩ ના રોજ મારી રહી તમા કોર્ટને કિલ્લો કરીને આવશે.

પશ્ચિમ રેલવે
પાર્સલ SLR ભાડે આપવા માટેના કરાર માટે ઇ-ઓક્શન
મુંબઈ ડિવિઝનમાંથી પારડી ઈતમને પાર્સલ SLR ભાડે આપવાના કરાર માટે ઇ-ઓક્શનને આમંત્રિત સમવાળાં આપ્યું છે. રૂા IREPS વેબસાઈટ પર પાર્સલની જ પ્રકલિત કરવામાં આવી છે, ડિવિઝની નોંધ મુજબ સમવાળાં આપી છે.
ઓક્શન ડેટાલોઝ નં-MMCT-PLS-23-15
લોક નં.
22931-SLR-R1-BOTS-JSM-22-1 12490-SLR-R1-ODR-BKN-22-1
12490-SLR-R1-ODR-BKN-22-1 12936-SLR-F1-ST-BOTS-22-1
12267-SLR-R1-MMCT-NAPA-22-1 12996-SLR-R1-BOTS-AII-22-1
12936-SLR-R1-ST-BOTS-22-1 19093-SLR-F2-BL-ADI-22-1
20929-SLR-F1-ST-AMI-22-1 20929-SLR-R1-ST-AMI-22-1
22931-SLR-F1-BOTS-JSM-22-1 19093-SLR-R1-BL-ADI-22-1
ઈ-ઓક્શનની તારીખ અને સમય: લોક માટે ઇ-ઓક્શન ૩૧. ૦૩. ૨૦૨૩ ના રોજ ૧૨:૦૦ કલાકે શરૂ થશે. ૩૦ મિનિટમાં પ્રારંભિક સમવાળાં સમવાળાં. ૦૯૦૬
અને ઈમેલ કરે: www.irps.gov.in અને ટ્વિટ્ટર પર www.twitter.com/WsRly

અહેર નોટીસ
મે.પારડીના એડીશનલ સીવિલ જજ અને જ્યુડી.મેટુ.
ફ.ક.સાહેબની હોર્ટમાં, મુ.પારડી, જિ.વલસાડ
પરવુકા અસ્ટુ નં-૦૯/૨૦૨૨
મુકાદ ઠા.૨૪/૦૩/૨૦૨૩
અવગણ: કોલેક્ટર ઈમરજન્સી કાર્યાલય
રો.૨૦૧, સોલો કોલેક્ટર ડિવિઝન, બી-૨૦૧, લોક ૨૦૧૨ કોલેક્ટર, નોબલ, સાને (ટે.ક) ૪૦૦ ૬૦૨
મો.૯૦૦૦૮૦૦૩૩૧ (વ.શી.સેલ.૨૫૨.૫૬૦૨)
સામવાળા: વીક એડિટરશ્રી, સામ પંચાયત-કુલવાડ, ઠા.પારડી, જિ.વલસાડ
સાચી તમામ સંબંધિત પક્ષકારોને આ અહેર નોટીસથી જાણ કરવામાં આવે છે કે, આ કમના અવગણ કોલેક્ટર ઈમરજન્સી કાર્યાલયને આરોગી સહાયતા ડિવિઝન નંબર ૧૦૧ પિલા નામે હવમગી માવકુલ કાર્યાલય મુકાદ તારીખ ૦૯/૦૩/૨૦૨૩ના રોજ મેનેજર-કોલેક્ટર પારડી, ઠા.પારડી, જિ.વલસાડમાં સરકારી ઈન્સ્ટોલેશન થયેલ છે. જે મરહુમી નોંધ સરકારી હકને લઈ લઈ. મરહુમે તેમના મિલાન મરહુમ ઘણાની સરકારી કમલકાર તથા સમગ્ર કમલકાર રહી જરૂરી હોય માટે લોક ઓફિસરશ્રી, પારડી નગરપાલિકા, ઠા.પારડી, જિ.વલસાડની કચેરીને કરવાય રા ર ઈમેલ સરકારી મેમોરી ટેલર છે. આવી મરહુમની સહાય સામે કોઈપણ ઈતમને કોઈ વંધી વા હકલત છે, તો તેમને આ અહેર નોટીસ પ્રસિદ્ધ થયેથી, આરોગી સહાયતા ડિવિઝન મુનવાલ વડીલ મારકેટ હાવર રહેશે. જો તેમ કમમાં કહુલ કરશે, તો

ASSAM POWER DISTRIBUTION COMPANY LIMITED
(A Govt. of Assam Public Limited Company)
REQUEST FOR PROPOSAL
RFP Notice No.: CGM/Com & EE/APDCL/Banking/2022/26 dt. 20-03-2023
APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 for the utility/trader. The detail is available in APDCL website www.apdcl.org.
Last date for submission is 10-04-2023.
Sd/- Chief General Manager (Com & EE), APDCL
Bijulee Bhawan, Paltanbazar, Guwahati - 1
Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
Tender No: 119/2022-23/KWA/PHC/TVA(RT-1)(I)-17067/2022
JMM-5th SSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandalam Thekkera panchayat including road restoration works. EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in
KWA-JB-GL-6-1881-2022-23
Superintending Engineer
PH Circle, Pathanamthitta

KERALA WATER AUTHORITY e-Tender Notice
Tender No: He T No.113/2022-23/SEC
Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I- KLM SSO1 and for commissioning of Karumali Vadi pumping station balance works EMD : Rs. 500000 Tender fee : Rs. 16540-2978 Last Date for submitting Tender : 10-04-2023 02:00pm Phone : 0472475293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in
KWA-JB-GL-6-1892-2022-23
Superintending Engineer
PH Circle, Kollam

KIFS HOUSING FINANCE LIMITED PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE
Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Elitbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.
KIFS HOUSING FINANCE LIMITED
C-902, Lotus Corporate Park, Graham Firth Compound, Western Express Highway, Goregaon (East), Mumbai-400063.
Tel: +91 22 61796400
Date: 21/03/2023

VIP Industries Limited
5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025
NOTICE
Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s).
Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775
Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED

Corporate Identification Number: U51496MH2008PLC184997
Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Speciality Chemicals Private Limited" under the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Speciality Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016, our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.
Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.
Contact Person: Mr. Hemal Vasantra Mehta, Managing Director
Tel No: 022- 42221111 | Email Id: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantra Mehta and Mr. Sachin Vasantra Mehta

BASIS OF ALLOTMENT
PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹5,009.55 LAKHS (THE "ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor or would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1 : 1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1 : 1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1 : 1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1 : 1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1 : 1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1 : 1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1 : 1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity Shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)
Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and firm basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FII/FPis	MFs	NBFCs	OTHs	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)
The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹ 73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalised in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity Shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalised in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before **March 17, 2023** and payment to non-Syndicate brokers have been issued on **March 20, 2023**. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before **March 20, 2023** for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on **March 22, 2023**.
Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("ROC").

INVESTORS, PLEASE NOTE

These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.
All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFINTECH
KFIN TECHNOLOGIES LIMITED
Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana.
Tel: +91 40 6716 2222/ 180034 54001;
E-mail: airward.ris@kfintech.com | Website: www.kfintech.com
Investor Service e-mail: spil ipo@kfintech.com
Contact person: M Murali Krishna | SEBI Registration No.: INR000000221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited
Sd/-
Hemal Vasantra Mehta
Managing Director
DIN: 02211121

Date: Mumbai
Date: March 20, 2023

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the ROC on March 16, 2023 and thereafter with the SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited <https://www.bseindia.com/and> on the websites of the BRLM, Grexit Corporate Services Limited at <https://grexitcorporate.com/ipo/investors> should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION

The Corrigendum is with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).
Attention of Investors is drawn
"On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, it will be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."

The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

BID/ISSUE PERIOD
ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023
BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023
BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 25(3) of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs"), the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalised at ₹ 73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 56,998,400/-.

The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1.6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,20,000	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,600.00	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,000.00	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,800.00	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,000.00	7,80,800	1.06
Total (A)	2,781	72,72,000	53,08,17,600.00	68,62,400	1.06	
6.	Underwriters* (B)	1	4,22,400	3,08,35,200.00	-	0.00
Grand Total (A + B)	2,782	76,94,400	56,16,52,800	68,62,400	1.12	

*Unsubscribed portion of 4,22,400 Equity shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:

A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.88
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
TOTAL		1,02,57,600	100.00		

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.

1) Allotment to Retail Individual Investors (After Technical Rejections)

The Basis of Allotment to the Retail Individual Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 73.00 per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 42,72,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	42,72,000	100.00	1600	1:1	42,72,000	0

Includes spilled over of 6,20,800 Equity Shares from NIB category.

2) Allotment to Non-Institutional Investors (After Technical Rejections)

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

FORM G INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESS ACROSS INDIA

(Under Regulation 36A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

RELEVANT PARTICULARS	
1. Name of the Corporate Debtor along with CIN / PAN	Future Supply Chain Solutions Limited CIN: L63030MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jageshwar - Vikhroli Link Road, Jogeshwari East, Mumbai 400069
3. URL of website	https://www.futurechain.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workmen	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futurechain.fsc@gmail.com
9. Eligibility for resolution applicants under section 25(2)(h) of the Code is available at:	Details can be sought by emailing futurechain.fsc@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futurechain.fsc@gmail.com

Date : 20/03/2023
Place: Mumbai
Sd/-
Rajan Rawat
Resolution Professional
In the matter of Future Supply Chain Solutions Limited
AFA Vaidit Up to 12-12-2023
Address: B-602, Azziano, Rustomjee House, Majwada, Thane West, Mumbai-400061
Correspondence Address: 144, Mittal Court, B Wing, 14th Floor, Nariman Point, Mumbai, Maharashtra, 400021

LANCO BABANDH POWER LIMITED - (IN LIQUIDATION)

Liquidator's Address: E-10A, Kailash Colony, Greater Kailash-I, New Delhi-110048
Email Id: assetsale@saainvolency.in, lancobabandh@saainvolency.in
Contact No: +91 880065284 - Mr. Puneet Sachdeva and Mr. Raj Kumar

E-AUCTION
Sale of Assets under Insolvency and Bankruptcy Code, 2016
Date and Time of E

ASSAM POWER DISTRIBUTION COMPANY LIMITED
(A Govt. of Assam Public Limited Company)

REQUEST FOR PROPOSAL
RFP Notice No.: CGM (Com & EE)/APDCL/Banking/2022/26 dt. 20-03-2023

APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 from the utility/trader. The detail is available in APDCL website www.apdcl.org.

Last date for submission is 10-04-2023.

Sd/- Chief General Manager (Com & EE), APDCL
Bijulee Bhawan, Paltanbazar, Guwahati - 1

Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
Tender No: 119/2022-23/KWA/PHC/TVA(RT-1)(I-17067/2022)

JJM -5th SSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandalam Thekkera panchayat including road restoration works. EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

KWA-JB-GL-6-1881-2022-23

Superintending Engineer
PH Circle, Pathanamthitta

KERALA WATER AUTHORITY e-Tender Notice
Tender No: He T No.113/2022-23/SEC

Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I- KLM SSO1 and for commissioning of Karumali Vadi pumping station balance works EMD : Rs. 500000 Tender fee : Rs. 16540-2978 Last Date for submitting Tender : 10-04-2023 02:00pm Phone : 04724745293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

KWA-JB-GL-6-1892-2022-23

Superintending Engineer
PH Circle, Kollam

KIFS HOUSING FINANCE LIMITED PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE

Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Elitbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.

KIFS HOUSING FINANCE LIMITED
C-902, Lotus Corporate Park, Graham Firth Compound, Western Express Highway, Goregaon (East), Mumbai-400063.
Tel: +91 22 61796400

Date: 21/03/2023

VIP Industries Limited
5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025

NOTICE
Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s). Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775

Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED

Corporate Identification Number: U51496MH2008PLC184997

Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Speciality Chemicals Private Limited" under the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Speciality Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016, our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.

Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.

Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director
Tel No: 022- 42221111 | Email Id: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta

BASIS OF ALLOTMENT

PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹5,009.55 LAKHS (THE "ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1 : 1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1 : 1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1 : 1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1 : 1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1 : 1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1 : 1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1 : 1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)
Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and final basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FII/FPis	MFs	NBFCs	OTHs	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)
The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹ 73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalised in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalised in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before **March 17, 2023** and payment to non-Syndicate brokers has been issued on **March 20, 2023**. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before **March 20, 2023** for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on **March 22, 2023**.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("ROC").

INVESTORS, PLEASE NOTE

These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFINTECH
KFIN TECHNOLOGIES LIMITED
Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana.
Tel: +91 40 6716 2222/ 180034 54001;
E-mail: airward.ris@kfintech.com | Website: www.kfintech.com
Investor grievance e-mail: slip.ipo@kfintech.com
Contact person: M Murali Krishna | SEBI Registration No.: INR000000221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited

Sd/-
Hemal Vasantrai Mehta
Managing Director
DIN: 02211121

Date: March 20, 2023

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the ROC on March 16, 2023 and thereafter with the SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited <https://www.bseindia.com/and> on the websites of the BRLM, Grexit Corporate Services Limited at <https://grexitcorporate.com/ipo/investors> should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION

The Corrigendum is with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).

Attention of Investors is drawn
"On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, it will be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."

The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

BID/ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023

BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023

BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 25(3) of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs"), the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalised at ₹ 73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 56,998,400/-.

The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1.6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,20,000	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,60,000	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,00,000	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,80,000	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,00,000	7,80,800	1.06
Total (A)	2,781	72,72,000	53,08,17,60,000	68,62,400	1.06	
6.	Underwriters* (B)	1	4,22,400	3,08,35,20,000	-	0.00
Grand Total (A + B)	2,782	76,94,400	56,16,52,800	68,62,400	1.12	

*Unsubscribed portion of 4,22,400 Equity shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:

A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.88
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
TOTAL		1,02,57,600	100.00		

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.

1) Allotment to Retail Individual Investors (After Technical Rejections)

The Basis of Allotment to the Retail Individual Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 73.00 per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 47,20,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	47,20,000	100.00	1600	1:1	47,20,000	0

Includes spilled over of 6,20,800 Equity Shares from NIB category.

2) Allotment to Non-Institutional Investors (After Technical Rejections)

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

FORM G INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESS ACROSS INDIA

(Under Regulation 38A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

RELEVANT PARTICULARS	
1. Name of the Corporate Debtor along with CIN / PAN	Future Supply Chain Solutions Limited CIN: L63030MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jageshwar - Vikhroli Link Road, Jogeshwari East, Mumbai 400069
3. URL of website	https://www.futurechain.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workmen	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futurechain.fsc@gmail.com
9. Eligibility for resolution applicants under section 25(2)(h) of the Code is available at:	Details can be sought by emailing futurechain.fsc@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futurechain.fsc@gmail.com

Date : 20/03/2023
Place: Mumbai
Sd/-
Rajan Rawat
Resolution Professional
In the matter of Future Supply Chain Solutions Limited
AFA Vaidi Up to 12-12-2023
Address: B-602, Azziano, Rustomjee House, Majwada, Thane West, Mumbai-400061
Correspondence Address: 144, Mittal Court, B Wing, 14th Floor, Nariman Point, Mumbai, Maharashtra, 400021

SALE NOTICE Lanco Babandh Power Limited - (IN LIQUIDATION)

Liquidator: Mr. Sanjay Gupta
Liqudator's Address: E-10A, Kailash Colony, Greater Kailash-I, New Delhi -110048
Email Id: assetsale@saainsoolvency.in, lancobabandh@saainsoolvency.in
Contact No: +91 8800

ASSAM POWER DISTRIBUTION COMPANY LIMITED
 (A Govt. of Assam Public Limited Company)
REQUEST FOR PROPOSAL
 RFP Notice No.: CGM (Com & EE)/APDCL/Banking/2022/76 dt. 20-03-2023
 APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 from the utility/ trader. The detail is available in APDCL website www.apdcl.org.
 Last date for submission is 10-04-2023.
 Sd/- Chief General Manager (Com & EE), APDCL
 Bijulee Bhawan, Paltanbazar, Guwahati - 1
 Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
 Tender No: 119/2022-23/KWA/PHC/TVA/RI-1/17067/2022
 JIM -5th SSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandamali Thekkera panchayath including road restoration works. **EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in**
KWA-JB-GL-6-1881-2022-23
 Superintending Engineer
 PH Circle, Pathanamthitta

KERALA WATER AUTHORITY e-Tender Notice
 Tender No: Re 1 No.113/2022-23/SE/C
 Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I- KLM SSO1 and for commissioning of Karumali Vadi pumping stations balance works **EMD : Rs. 500000 Tender fee : Rs. 16540-2978 Last Date for submitting Tender: 10-04-2023 02:00pm Phone : 04742745293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in**
KWA-JB-GL-6-1892-2022-23
 Superintending Engineer
 PH Circle, Kollam

KIFS HOUSING FINANCE LIMITED PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE
 Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Ellisbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from **March 20, 2023**. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.
KIFS HOUSING FINANCE LIMITED
 C-902, Lotus Corporate Park, Graham Firth Compound, Western Express Highway, Goregaon (East), Mumbai-400063.
 Tel: +91 22 61796400
 Date: 21/03/2023

VIP Industries Limited
 5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025
NOTICE
 Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s). Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775
Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED
 Corporate Identification Number: U51496MH2008PLC184997
 Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Specialty Chemicals Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Specialty Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016. Our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.
Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.
Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director
Tel No: 022-42221111 | **Email ID:** compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta
BASIS OF ALLOTMENT
PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUEPRICE") AGGREGATING TO ₹5,009.55 LAKHS ("THE ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.
ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:
 a. There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
 b. Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor or would adversely impact our operations and, consequently, our business.
 c. We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
 d. There are no long-term supply agreements with our vendors / suppliers.
 e. The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
 f. Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
 g. Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth

ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023
BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023
BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 25(3) of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.
 The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalized at ₹ 73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 56,998,400/-.
 The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1,6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,200.00	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,600.00	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,000.00	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,800.00	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,000.00	7,80,800	1.06
6.	Total (A)	2,781	72,72,000	53,08,17,600.00	68,62,400	1.06
7.	Underwriters* (B)	1	4,22,400	3,08,35,200.00	-	0.00
	Grand Total (A+B)	2,782	76,94,400	56,16,52,800	68,62,400	1.12

*Unsubscribed portion of 4,22,400 equity shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:
 A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.88
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
	TOTAL	1,02,57,600	100.00		

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.
1) Allotment to Retail Individual Investors (After Technical Rejections)
 The Basis of Allotment to the Retail Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of ₹ 73.00 per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 42,72,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	42,72,000	100.00	1600	1:1	42,72,000	0

Includes spilled over of 6,20,800 Equity Shares from NIB category.

2) Allotment to Non-Institutional Investors (After Technical Rejections)
 The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1:1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1:1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1:1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1:1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1:1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1:1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1:1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity shares spilled over the Merchant banker Underwriters obligation.
3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)
 Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and firm basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FIs/FPIs	MFs	NBFCs	OTHS	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)
 The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹ 73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalised in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity Shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalised in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before **March 17, 2023** and payment to non-Syndicate brokers has been issued on **March 20, 2023**. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before **March 20, 2023** for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on **March 22, 2023**.
Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("ROC").

INVESTORS, PLEASE NOTE
 These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFIN TECHNOLOGIES LIMITED
 Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana
 Tel: +91 40 6716 2222 | 180034 54001;
 E-mail: eisward.ris@kfintech.com | Website: www.kfintech.com
 investor grievance e-mail: spii ipo@kfintech.com
 Contact person: M Murali Krishna | SEBI Registration No.: INR000000221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited
 Sd/-
Hemal Vasantrai Mehta
 Managing Director
 DIN: 02211121

Place: Mumbai
Date: March 20, 2023.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.
Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the ROC on March 16, 2023 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited at https://www.bsesme.com/ and on the websites of the BRLM, GreteX Corporate Services Limited at https://gretelexcorp.com/ ipo/investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION
 The Corrigendum with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).
Attention of Investors is drawn
 "On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, it will be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."
 The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

FORM G INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESS ACROSS INDIA
 [Under Regulation 38A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016]

RELEVANT PARTICULARS	
1. Name of the Corporate Debtor along with CIN / PAN	Future Supply Chain Solutions Limited CIN: L63030MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jogeshwari- Vikhroli Link Road, Jogeshwari East, Mumbai 400069
3. URL of website	https://www.futureupplychains.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workmen	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futuresupply.lbc@gmail.com
9. Eligibility for resolution applicants under section 25(2)(h) of the Code is available at:	Details can be sought by emailing futuresupply.lbc@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futuresupply.lbc@gmail.com

Date: 20/03/2023
 Place: Mumbai
 Sd/- **Rajan Rawat**
 Resolution Professional
 In the matter of Future Supply Chain Solutions Limited
 AFA Valid Up to 12-12-2023
 Address: B-602, Azziano, Rustomjee Meadows, Thane West, Mumbai-400601
 Correspondence Address: 144, Mittal Court, B Wing, 14th Floor, Naarman Point, Mumbai, Maharashtra, 400021

SALE NOTICE
LANCO BABANDH POWER LIMITED- (IN LIQUIDATION)
 Liquidator: Mr. Sanjay Gupta
 Liquidator's Address: E-10A, Kailash Colony, Greater Kailash-I, New Delhi -110048
 Email ID: assetsale@saainsolvency.in, lanco.babandh@saainsolvency.com
 Contact No: +91 8800865284 - Mr. Puneet Sachdeva and Mr. Raj Kumar

E-AUCTION
 Sale of Assets under Insolvency and Bankruptcy Code, 2016
Date and Time of E-Auction: 19th April, 2023 at 3:00 pm-5:00 pm
 (With unlimited extension of 5 minutes each)
Last date of Receiving EMD Submission: 17th April, 2023 before 3:00 PM
Last date for Submission of Eligibility Documents by prospective bidder:
 From 21st March, 2023 to 03rd April, 2023

Sale of Assets and Properties owned by **Lanco Babandh Power Ltd (In Liquidation)** forming part of Liquidation Estate formed by the Liquidator, appointed by the Hon'ble National Company Law Tribunal, Hyderabad Bench vide order dated 27th November, 2019. The sale will be done by the undersigned through the E-auction platform i.e. M/S National E-Governance Services Ltd (NeSL), having website at: https://nbiid.nesl.co.in/vpplogin.

Particulars of Asset	Block	Reserve Price (INR)	Initial EMD (INR)	Incremental Value (INR)
Plant and Machinery at Thermal Power Plant of Lanco Babandh Power Ltd at Vatakapattan Port	A	27,25,000	1,30,000	10,000

Terms and Condition of the E-auction are as under
 1. E-Auction will be conducted on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS" through approved service provider i.e. i.e. NeSL (National E-Governance Services Ltd.)
 2. It is clarified that this invitation purports to invite prospective bidders and does not create any kind of binding obligation on the part of the Liquidator or the Company to effectuate the sale. The Liquidator reserves the right to cancel or modify the process and/or not to accept and/or disqualify any interested party / potential investor / bidder without assigning any reason and without any liability.
 3. The custody of plant and machinery with respect to Block A shall only be given to the successful bidder after release of assets by the port authorities, for which, proceedings are ongoing before Hon'ble NCLT, Hyderabad Bench vide order dated 27th November, 2019. The Liquidator (in the matter of Lanco Babandh Power Limited) vs VPL (In Liquidation) CFS Pvt Ltd & Anr. The matter is reserved for orders.

All the terms and conditions are to be mandatorily referred from the website of AAAs Insolvency Professionals LLP i.e. https://insolvencyandbankruptcy.in/public-announcement/lanco-babandh-power-limited/ and from the E-Auction Process Document, prior to submission of EMD and participation in the process.
 Sd/- **Sanjay Gupta, Liquidator**
Lanco Babandh Power Limited in Liquidation
 IBBI Regn. No. IBBI/PA-02/IN-00743/201

ASSAM POWER DISTRIBUTION COMPANY LIMITED
(A Govt. of Assam Public Limited Company)
REQUEST FOR PROPOSAL
RFP Notice No.: CGM (Com & EE)/APDCL/Banking/2022/26 dt. 20-03-2023
APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 for the utility/trader. The detail is available in APDCL website www.apdcl.org.
Last date for submission is 10-04-2023.
Sd/- Chief General Manager (Com & EE), APDCL
Bijulee Bhawan, Paltanbazar, Guwahati - 1
Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
Tender No: 119/2022-23/KWA/PHC/TVA(RT-1)(I)-17067/2022
JMM -5th SSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandalam Thekkera panchayat including road restoration works. **EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in**
KWA-JB-GL-6-1881-2022-23
Superintending Engineer
PH Circle, Pathanamthitta

KERALA WATER AUTHORITY e-Tender Notice
Tender No: He T No.113/2022-23/SEC
Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I- KLM SSO1 and for commissioning of Karumali Vadi pumping station balance works. **EMD : Rs. 500000 Tender fee : Rs. 16540-2978 Last Date for submitting Tender : 10-04-2023 02:00pm Phone : 04724745293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in**
KWA-JB-GL-6-1892-2022-23
Superintending Engineer
PH Circle, Kollam

KIFS HOUSING FINANCE LIMITED PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE
Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Elitbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.
KIFS HOUSING FINANCE LIMITED
C-902, Lotus Corporate Park, Graham Firth Compound, Western Express Highway, Goregaon (East), Mumbai-400063.
Tel: +91 22 61796400
Date: 21/03/2023

VIP Industries Limited
5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025
NOTICE
Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s).
Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775
Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED

Corporate Identification Number: U51496MH2008PLC184997
Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Speciality Chemicals Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Speciality Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016, our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.
Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.
Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director
Tel No: 022- 42221111 | Email Id: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta

BASIS OF ALLOTMENT
PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹5,009.55 LAKHS ("THE ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor or would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1 : 1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1 : 1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1 : 1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1 : 1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1 : 1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1 : 1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1 : 1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity Shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)
Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and firm basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FII/FPis	MFs	NBFCs	OTHs	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)
The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹ 73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalised in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity Shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalised in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before **March 17, 2023** and payment to non-Syndicate brokers has been issued on **March 20, 2023**. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before **March 20, 2023** for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on **March 22, 2023**.
Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("ROC").

INVESTORS, PLEASE NOTE

These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFINTECH
KFIN TECHNOLOGIES LIMITED
Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana.
Tel: +91 40 6716 2222/ 180034 54001;
E-mail: airward.ris@kfintech.com | Website: www.kfintech.com
Investor Service e-mail: slp.ipoc@kfintech.com
Contact person: M Murali Krishna | SEBI Registration No.: INR000000221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited
Sd/-
Hemal Vasantrai Mehta
Managing Director
DIN: 02211121

Date: March 20, 2023

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the ROC on March 16, 2023 and thereafter with the SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited <https://www.bseindia.com> and on the websites of the BRLM, Grexit Corporate Services Limited at <https://grexitcorporate.com>. IPO/Investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION

The Corrigendum is with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).
Attention of Investors is drawn
"On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, it shall be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."

The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

BID/ISSUE PERIOD
ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023
BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023
BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 25(3) of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs"), the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalised at ₹ 73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 56,998,400/-.

The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1.6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,20,000	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,60,000	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,00,000	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,80,000	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,00,000	7,80,800	1.06
Total (A)	2,781	72,72,000	53,08,17,60,000	68,62,400	1.06	
6.	Underwriters* (B)	1	4,22,400	3,08,35,20,000	-	0.00
Grand Total (A + B)	2,782	76,94,400	56,16,52,800	68,62,400	1.12	

*Unsubscribed portion of 4,22,400 Equity Shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:

A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.88
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
TOTAL		1,02,57,600	100.00		

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.

1) Allotment to Retail Individual Investors (After Technical Rejections)

The Basis of Allotment to the Retail Individual Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 73.00 per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 42,72,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	42,72,000	100.00	1600	1:1	42,72,000	0

Includes spilled over of 6,20,800 Equity Shares from NIB category.

2) Allotment to Non-Institutional Investors (After Technical Rejections)

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

FORM G INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESS ACROSS INDIA

(Under Regulation 36A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

RELEVANT PARTICULARS	
1. Name of the Corporate Debtor along with CIN / PAN	Future Supply Chain Solutions Limited CIN: L63030MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jageshwar - Vikhroli Link Road, Jogeshwari East, Mumbai 400069
3. URL of website	https://www.futurechain.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workmen	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futurechain.fsc@gmail.com
9. Eligibility for resolution applicants under section 25(2)(h) of the Code is available at:	Details can be sought by emailing futurechain.fsc@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futurechain.fsc@gmail.com

Date : 20/03/2023
Place: Mumbai
Sd/-
Rajan Rawat
Resolution Professional
In the matter of Future Supply Chain Solutions Limited
AFA Vaidi Uo to 12-12-2023
Address: B-602, Azzadino, Rustomjee House, Majwada, Thane West, Mumbai-400061
Correspondence Address: 144, Mittal Court, B Wing, 14th Floor, Nariman Point, Mumbai, Maharashtra, 400021

SALE NOTICE Lanco Babandh Power Limited - (IN LIQUIDATION)

Liquidator's Address: E-10A, Kailash Colony, Greater Kailash-I, New Delhi -110048
Email Id: assetsale@saainsoolvency.in, lancobabandh@saainsoolvency.in
Contact No.: +91 880065284 - Mr. Puneet Sachdeva and Mr. Raj Kumar

E-AUCTION
Sale of Assets under Insolvency and Bankruptcy Code, 2016
Date and Time of E-Auction: 19th April, 2023 at 3:00 pm-5:00 pm
(With unlimited extension of 5 minutes each)
Last date of Receiving EMD Submission:

ASSAM POWER DISTRIBUTION COMPANY LIMITED
(A Govt. of Assam Public Limited Company)

REQUEST FOR PROPOSAL
RFP Notice No.: CGM (Com & EE)/APDCL/Bank/2022/26 dt. 20-03-2023

APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 from the utility/ trader. The detail is available in APDCL website www.apdcl.org.

Last date for submission is 10-04-2023.

Sd/- Chief General Manager (Com & EE), APDCL
Bijulee Bhawan, Patanbazar, Guwahati - 1

Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice

Tender No: 119/2022-23/KWA/PHC/1(VLA/HR-1)(G-17067/2022)

JM - 5th SSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandalam Thekkkara panchayath including road restoration works. EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00 pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

KWA-JB-GL-6-1881-2022-23

Superintending Engineer
PH Circle, Pathanamthitta

KERALA WATER AUTHORITY e-Tender Notice

Tender No: Re 1 No.113/2022-23/SE/O

Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I - KLM SSO1 and for commissioning of Karumali Vadi pumping stations balance works EMD : Rs. 500000 Tender fee : Rs. 16540+2978 Last Date for submitting Tender : 10-04-2023 02:00 pm Phone : 04742745293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

KWA-JB-GL-6-1892-2022-23

Superintending Engineer
PH Circle, Kollam

KIFS HOUSING FINANCE LIMITED
PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE

Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Ellisbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.

KIFS HOUSING FINANCE LIMITED
C-902, Lotus Corporate Park, Graham Firth Compound, Western Express Highway, Goregaon (East), Mumbai-400063.
Tel: +91 22 61796400
Date: 21/03/2023

VIP Industries Limited
5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025

NOTICE

Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s).

Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775

Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED

Corporate Identification Number: U51496MH2008PLC184997

Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Speciality Chemicals Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Speciality Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and wide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016. Our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further Details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.

Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.

Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director

Tel No: 022- 42221111 | Email Id: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta

BASES OF ALLOTMENT

PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUEPRICE") AGGREGATING TO ₹5,009.55 LAKHS ("THE ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor or would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licences or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth.

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1:1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1:1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1:1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1:1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1:1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1:1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1:1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity Shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)

Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and firm basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FII/FPIs	MFs	NBFCs	OTHS	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)

The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹ 73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalized in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalized in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before March 17, 2023 and payment to non-Syndicate brokers have been issued on March 20, 2023. In case the same is not received within ten days, investors may contact the Registrar to the issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before March 20, 2023 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on March 22, 2023.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("RoC").

INVESTORS, PLEASE NOTE

These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/Sole applicant, Serial number of the ASBA form, number of Equity Shares bid, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:



KFIN TECHNOLOGIES LIMITED
Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana
Tel: +91 40 6716 2222 / 180034 54001
E-mail: investor.ris@kfintech.com | www.kfintech.com
Investor grievance e-mail: spit.ipo@kfintech.com
Contact person: M Murali Krishna | SEBI Registration No.: INF000090221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited
Sd/-
Hemal Vasantrai Mehta
Managing Director
DIN: 02211121

Place: Mumbai
Date: March 20, 2023

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the RoC on March 16, 2023 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited at www.bseindia.com and on the websites of the BRLM, Grete Corporate Services Limited at www.gretec.com and www.ipoliprospectus.com and on the website of the Bidder. The applicable provisions of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, (Securities) Standard on General Meetings issued by the Institute of Company Secretaries of India ("ISS-21") and in terms of General Circular No. 14/2020 dated April 08, 2020, General Circular No. 17/2020, dated April 13, 2020, General Circular No. 22/2020 dated June 15, 2020, General Circular No. 33/2020 dated September 28, 2020, General Circular No. 39/2020 dated December 31, 2020, General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 32/2022 dated May 5, 2022 and General Circular No. 11/2022 dated October 26, 2022 issued by the Ministry of Corporate Affairs ("MCA Circulars") and SEBI Circular No. SEBI/CFD/POD-2/P/CIR/2023/4 dated January 05, 2023 (the "SEBI Circulars"), and other applicable laws and regulations, if any, each as amended from time to time, the Company is seeking approval of its members for passing of special resolution by way of postal ballot as stated in the postal ballot notice dated March 20, 2023 ("Postal Ballot Notice"). The Company has completed the dispatch of the Postal Ballot Notice on March 20, 2023.

It may please be noted that the dispatch of Postal Ballot Notice to the Members has been made only through electronic mode to those Members whose names appear in the Registrar of Members or in the Register of Beneficial Owners maintained by the Depositories (i.e. Depository Participants), as on March 16, 2023 ("Cut-off Date") on their e-mail IDs registered with Depositories / Depository Participants / Registrar and Share Transfer Agent of the Company. The requirement of sending physical copies of the Postal Ballot Notice and Postal Ballot Form has been dispensed with, under the MCA Circulars. However, it is clarified that all the persons who are Members of the Company as on March 10, 2023 (including those Members who may not have received the Notice due to non-registration of their e-mail IDs with the Depositories / Depository Participants / Registrar and Share Transfer Agent) will be entitled to vote in relation to the Resolution specified in the notice and any person who is not a Member as on the Cut-off date should treat this Postal Ballot Notice for information purpose only.

In compliance with the provisions of the Applicable Laws, the Company is providing e-voting facility to the Members to cast their vote by electronic means on the Resolution set forth in the Postal Ballot Notice through e-voting services provided by National Securities Depository Limited ("NSDL"). The Members have an option to exercise their vote either electronically or by way of physical Postal Ballot Forms.

The procedure / instructions for e-voting / is given in the Postal Ballot Notice. The e-voting facility is available from 9:00 a.m. (IST) on Tuesday, March 21, 2023 up to 5:00 p.m. (IST) on Wednesday, April 19, 2023. The e-voting module will be disabled by NSDL for voting thereafter.

The copy of the said Postal Ballot Notice is being made available on the website of Company, viz., www.multibaseindia.com and on the website of the Registrar of Members at www.bseindia.com and on the website of the Bidder at www.kfintech.com and also on the website of the Depositories / Depository Participants / Registrar and Share Transfer Agent at www.evoting.nsdl.com. It is also being made available on the website of the NSDL at www.evoting.nsdl.com. Any Member desirous of obtaining the said Postal Ballot Forms may also write to pamy.kamani@dupont.com.

Members desirous to cast their vote through Postal Ballot physically are requested to take printout of the Postal Ballot Form from any of the aforementioned websites, fill in the details and send the duly signed Postal Ballot Form in original, duly completed and signed, so as to physically reach the Scrutinizer at Mr. Dhruvil M. Shah, Partner of M/s. Dhruvil M. Shah & Co (FCs No. 0978 and Certificate of Practice No. 9021) have been appointed as the Scrutinizer for conducting the Postal Ballot and e-voting process in a fair and transparent manner.

The procedure / instructions for e-voting / is given in the Postal Ballot Notice. The e-voting facility is available from 9:00 a.m. (IST) on Tuesday, March 21, 2023 up to 5:00 p.m. (IST) on Wednesday, April 19, 2023. The e-voting module will be disabled by NSDL for voting thereafter.

The copy of the said Postal Ballot Notice is being made available on the website of Company, viz., www.multibaseindia.com and on the website of the Registrar of Members at www.bseindia.com and on the website of the Bidder at www.kfintech.com and also on the website of the Depositories / Depository Participants / Registrar and Share Transfer Agent at www.evoting.nsdl.com. It is also being made available on the website of the NSDL at www.evoting.nsdl.com. Any Member desirous of obtaining the said Postal Ballot Forms may also write to pamy.kamani@dupont.com.

Members desirous to cast their vote through Postal Ballot physically are requested to take printout of the Postal Ballot Form from any of the aforementioned websites, fill in the details and send the duly signed Postal Ballot Form in original, duly completed and signed, so as to physically reach the Scrutinizer at Mr. Dhruvil M. Shah, Partner of M/s. Dhruvil M. Shah & Co (FCs No. 0978 and Certificate of Practice No. 9021) have been appointed as the Scrutinizer for conducting the Postal Ballot and e-voting process in a fair and transparent manner.

The procedure / instructions for e-voting / is given in the Postal Ballot Notice. The e-voting facility is available from 9:00 a.m. (IST) on Tuesday, March 21, 2023 up to 5:00 p.m. (IST) on Wednesday, April 19, 2023. The e-voting module will be disabled by NSDL for voting thereafter.

The copy of the said Postal Ballot Notice is being made available on the website of Company, viz., www.multibaseindia.com and on the website of the Registrar of Members at www.bseindia.com and on the website of the Bidder at www.kfintech.com and also on the website of the Depositories / Depository Participants / Registrar and Share Transfer Agent at www.evoting.nsdl.com. It is also being made available on the website of the NSDL at www.evoting.nsdl.com. Any Member desirous of obtaining the said Postal Ballot Forms may also write to pamy.kamani@dupont.com.

Members desirous to cast their vote through Postal Ballot physically are requested to take printout of the Postal Ballot Form from any of the aforementioned websites, fill in the details and send the duly signed Postal Ballot Form in original, duly completed and signed, so as to physically reach the Scrutinizer at Mr. Dhruvil M. Shah, Partner of M/s. Dhruvil M. Shah & Co (FCs No. 0978 and Certificate of Practice No. 9021) have been appointed as the Scrutinizer for conducting the Postal Ballot and e-voting process in a fair and transparent manner.

The procedure / instructions for e-voting / is given in the Postal Ballot Notice. The e-voting facility is available from 9:00 a.m. (IST) on Tuesday, March 21, 2023 up to 5:00 p.m. (IST) on Wednesday, April 19, 2023. The e-voting module will be disabled by NSDL for voting thereafter.

The copy of the said Postal Ballot Notice is being made available on the website of Company, viz., www.multibaseindia.com and on the website of the Registrar of Members at www.bseindia.com and on the website of the Bidder at www.kfintech.com and also on the website of the Depositories / Depository Participants / Registrar and Share Transfer Agent at www.evoting.nsdl.com. It is also being made available on the website of the NSDL at www.evoting.nsdl.com. Any Member desirous of obtaining the said Postal Ballot Forms may also write to pamy.kamani@dupont.com.

Members desirous to cast their vote through Postal Ballot physically are requested to take printout of the Postal Ballot Form from any of the aforementioned websites, fill in the details and send the duly signed Postal Ballot Form in original, duly completed and signed, so as to physically reach the Scrutinizer at Mr. Dhruvil M. Shah, Partner of M/s. Dhruvil M. Shah & Co (FCs No. 0978 and Certificate of Practice No. 9021) have been appointed as the Scrutinizer for conducting the Postal Ballot and e-voting process in a fair and transparent manner.

The procedure / instructions for e-voting / is given in the Postal Ballot Notice. The e-voting facility is available from 9:00 a.m. (IST) on Tuesday, March 21, 2023 up to 5:00 p.m. (IST) on Wednesday, April 19, 2023. The e-voting module will be disabled by NSDL for voting thereafter.

The copy of the said Postal Ballot Notice is being made available on the website of Company, viz., www.multibaseindia.com and on the website of the Registrar of Members at www.bseindia.com and on the website of the Bidder at www.kfintech.com and also on the website of the Depositories / Depository Participants / Registrar and Share Transfer Agent at www.evoting.nsdl.com. It is also being made available on the website of the NSDL at www.evoting.nsdl.com. Any Member desirous of obtaining the said Postal Ballot Forms may also write to pamy.kamani@dupont.com.

Members desirous to cast their vote through Postal Ballot physically are requested to take printout of the Postal Ballot Form from any of the aforementioned websites, fill in the details and send the duly signed Postal Ballot Form in original, duly completed and signed, so as to physically reach the Scrutinizer at Mr. Dhruvil M. Shah, Partner of M/s. Dhruvil M. Shah & Co (FCs No. 0978 and Certificate of Practice No. 9021) have been appointed as the Scrutinizer for conducting the Postal Ballot and e-voting process in a fair and transparent manner.

The procedure / instructions for e-voting / is given in the Postal Ballot Notice. The e-voting facility is available from 9:00 a.m. (IST) on Tuesday, March 21, 2023 up to 5:00 p.m. (IST) on Wednesday, April 19, 2023. The e-voting module will be disabled by NSDL for voting thereafter.

The copy of the said Postal Ballot Notice is being made available on the website of Company, viz., www.multibaseindia.com and on the website of the Registrar of Members at www.bseindia.com and on the website of the Bidder at www.kfintech.com and also on the website of the Depositories / Depository Participants / Registrar and Share Transfer Agent at www.evoting.nsdl.com. It is also being made available on the website of the NSDL at www.evoting.nsdl.com. Any Member desirous of obtaining the said Postal Ballot Forms may also write to pamy.kamani@dupont.com.

Members desirous to cast their vote through Postal Ballot physically are requested to take printout of the Postal Ballot Form from any of the aforementioned websites, fill in the details and send the duly signed Postal Ballot Form in original, duly completed and signed, so as to physically reach the Scrutinizer at Mr. Dhruvil M. Shah, Partner of M/s. Dhruvil M. Shah & Co (FCs No. 0978 and Certificate of Practice No. 9021) have been appointed as the Scrutinizer for conducting the Postal Ballot and e-voting process in a fair and transparent manner.

The procedure / instructions for e-voting / is given in the Postal Ballot Notice. The e-voting facility is available from 9:00 a.m. (IST) on Tuesday, March 21, 2023 up to 5:00 p.m. (IST) on Wednesday, April 19, 2023. The e-voting module will be disabled by NSDL for voting thereafter.

The copy of the said Postal Ballot Notice is being made available on the website of Company, viz., www.multibaseindia.com and on the website of the Registrar of Members at www.bseindia.com and on the website of the Bidder at www.kfintech.com and also on the website of the Depositories / Depository Participants / Registrar and Share Transfer Agent at www.evoting.nsdl.com. It is also being made available on the website of the NSDL at www.evoting.nsdl.com. Any Member desirous of obtaining the said Postal Ballot Forms may also write to pamy.kamani@dupont.com.

Members desirous to cast their vote through Postal Ballot physically are requested to take printout of the Postal Ballot Form from any of the aforementioned websites, fill in the details and send the duly signed Postal Ballot Form in original, duly completed and signed, so as to physically reach the Scrutinizer at Mr. Dhruvil M. Shah, Partner of M/s. Dhruvil M. Shah & Co (FCs No. 0978 and Certificate of Practice No. 9021) have been appointed as the Scrutinizer for conducting the Postal Ballot and e-voting process in a fair and transparent manner.

The procedure / instructions for e-voting / is given in the Postal Ballot Notice. The e-voting facility is available from 9:00 a.m. (IST) on Tuesday, March 21, 2023 up to 5:00 p.m. (IST) on Wednesday, April 19, 2023. The e-voting module will be disabled by NSDL for voting thereafter.

The copy of the said Postal Ballot Notice is being made available on the website of Company, viz., www.multibaseindia.com and on the website of the Registrar of Members at www.bseindia.com and on the website of the Bidder at www.kfintech.com and also on the website of the Depositories / Depository Participants / Registrar and Share Transfer Agent at www.evoting.nsdl.com. It is also being made available on the website of the NSDL at www.evoting.nsdl.com. Any Member desirous of obtaining the said Postal Ballot Forms may also write to pamy.kamani@dupont.com.

Members desirous to cast their vote through Postal Ballot physically are requested to take printout of the Postal Ballot Form from any of the aforementioned websites, fill in the details and send the duly signed Postal Ballot Form in original, duly completed and signed, so as to physically reach the Scrutinizer at Mr. Dhruvil M. Shah, Partner of M/s. Dhruvil M. Shah & Co (FCs No. 0978 and Certificate of Practice No. 9021) have been appointed as the Scrutinizer for conducting the Postal Ballot and e-voting process in a fair and transparent manner.

The procedure / instructions for e-voting / is given in the Postal Ballot Notice. The e-voting facility is available from 9:00 a.m. (IST) on Tuesday, March 21, 2023 up to 5:00 p.m. (IST) on Wednesday, April 19, 2023. The e-voting module will be disabled by NSDL for voting thereafter.

The copy of the said Postal Ballot Notice is being made available on the website of Company, viz., www.multibaseindia.com and on the website of the Registrar of Members at www.bseindia.com and on the website of the Bidder at www.kfintech.com and also on the website of the Depositories / Depository Participants / Registrar and Share Transfer Agent at www.evoting.nsdl.com. It is also being made available on the website of the NSDL at www.evoting.nsdl.com. Any Member desirous of obtaining the said Postal Ballot Forms may also write to pamy.kamani@dupont.com.

Members desirous to cast their vote through Postal Ballot physically are requested to take printout of the Postal Ballot Form from any of the aforementioned websites, fill in the details and send the duly signed Postal Ballot Form in original, duly completed and signed, so as to physically reach the Scrutinizer at Mr. Dhruvil M. Shah, Partner of M/s. Dhruvil M. Shah &

ASSAM POWER DISTRIBUTION COMPANY LIMITED
 (A Govt. of Assam Public Limited Company)
REQUEST FOR PROPOSAL
 RFP Notice No.: CGM (Com & EE)/APDCL/Banking/2022/26 dt. 20-03-2023
 APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 from the utility/ trader. The detail is available in APDCL website www.apdcl.org.
 Last date for submission is 10-04-2023.
 Sd/- Chief General Manager (Com & EE), APDCL
 Bijulee Bhawan, Paltanbazar, Guwahati - 1
 Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
 Tender No: 119/2022-23/KW A/PHC/TVA/RI-1/17067/2022
 JIM -5th SSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandamali Thekkera panchayath including road restoration works. EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in
 KWA-JB-GL-6-1881-2022-23
 Superintending Engineer
 PH Circle, Pathanamthitta

KERALA WATER AUTHORITY e-Tender Notice
 Tender No: Re T No.113/2022-23/SE/C
 Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I- KLM SSO1 and for commissioning of Karumali Vadi pumping stations balance works EMD : Rs. 500000 Tender fee : Rs. 16540-2978 Last Date for submitting Tender: 10-04-2023 02:00pm Phone : 04742745293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in
 KWA-JB-GL-6-1892-2022-23
 Superintending Engineer
 PH Circle, Kollam

KIFS HOUSING FINANCE LIMITED PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE
 Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Ellisbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.
 KIFS HOUSING FINANCE LIMITED
 C-902, Lotus Corporate Park, Graham Firth Compound, Western Express Highway, Goregaon (East), Mumbai-400063.
 Tel: +91 22 61796400
 Date: 21/03/2023

VIP Industries Limited
 5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025
NOTICE
 Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s). Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775
 Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED

Corporate Identification Number: U51496MH2008PLC184997

Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Specialty Chemicals Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Specialty Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016. Our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further Details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.

Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.

Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director
 Tel No: 022-42221111 | Email ID: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta

BASIS OF ALLOTMENT

PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹5,009.55 LAKHS (THE "ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth.

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1:1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1:1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1:1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1:1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1:1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1:1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1:1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity Shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)

Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and firm basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FII/FPis	MFs	NBFCs	OTHS	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)

The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections):

The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalised in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections):

Unsubscribed portion of 4,22,400 equity shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalised in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before March 17, 2023 and payment to non-Syndicate brokers has been issued on March 20, 2023. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before March 20, 2023 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on March 22, 2023.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("ROC").

INVESTORS, PLEASE NOTE

These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFIN TECHNOLOGIES LIMITED
 Selanium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana
 Tel: +91 40 6716 2222 | 180034 54001;
 E-mail: eis@kfintech.com | Website: www.kfintech.com
 investor grievance e-mail: spii ipo@kfintech.com
 Contact person: M Murali Krishna | SEBI Registration No.: INR000000221

On behalf of Board of Directors

Sudarshan Pharma Industries Limited

Sd/-

Hemal Vasantrai Mehta

Managing Director

DIN: 02211121

Place: Mumbai
 Date: March 20, 2023.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the ROC on March 16, 2023 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited at https://www.bseindia.com/ and on the websites of the BRLM, Grex Corporate Services Limited at https://gretcorp.com/ ipo/investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION

The Corrigendum with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).

Attention of Investors is drawn

"On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, will be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."

The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

BID/ISSUE PERIOD
ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023
BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023
BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 25(3) of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalised at ₹73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹56,998,400/-.

The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1,6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,200.00	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,600.00	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,000.00	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,800.00	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,000.00	7,80,800	1.06
6.	Total (A)	2,781	72,72,000	53,08,17,600.00	68,62,400	1.06
6.	Underwriters* (B)	1	4,22,400	3,08,35,200.00	-	1.00
	Grand Total (A+B)	2,782	76,94,400	56,16,52,800	68,62,400	1.12

*Unsubscribed portion of 4,22,400 equity shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:

A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.88
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
	TOTAL	1,02,57,600	100.00		

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.

1) Allotment to Retail Individual Investors (After Technical Rejections)

The Basis of Allotment to the Retail Individual Investors, who have bid at cut-off Price or at or above the Issue Price of ₹73.00 per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 42,72,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	42,72,000	100.00	1600	1:1	42,72,000	0

Includes spilled over of 6,20,800 Equity Shares from NIB category

2) Allotment to Non-Institutional Investors (After Technical Rejections)

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

FORM G INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESS ACROSS INDIA

(Under Regulation 38A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

RELEVANT PARTICULARS	
1. Name of the Corporate Debtor along with CIN / PAN	Future Supply Chain Solutions Limited CIN: L63030MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jogeshwari- Vikhroli Link Road, Jogeshwari East, Mumbai 400069
3. URL of website	https://www.futureupplychains.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workmen	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futureupply.lbc@gmail.com
9. Eligibility for resolution applicants under section 25(2)(h) of the Code is available at:	Details can be sought by emailing futureupply.lbc@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futureupply.lbc@gmail.com

Date: 20/03/2023
 Place: Mumbai
 Sd/-
 Rajan Rawat
 Resolution Professional
 In the matter of Future Supply Chain Solutions Limited
 AFA Valid Up to 12-12-2023
 Address: B-602, Azziano, Rustomjee Meadows, Thane

ASSAM POWER DISTRIBUTION COMPANY LIMITED
(A Govt. of Assam Public Limited Company)

REQUEST FOR PROPOSAL
RFP Notice No.: CGM (Com & EE)/APDCL/Banking/2022/26 dt. 20-03-2023

APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 for the utility/trader. The detail is available in APDCL website www.apdcl.org.

Last date for submission is 10-04-2023.

Sd/- Chief General Manager (Com & EE), APDCL
Bijulee Bhawan, Paltanbazar, Guwahati - 1

Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
Tender No: 119/2022-23/KWA/PHC/TVA(RT-1)(I)-17067/2022

JJM -5th SSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandalam Thekkera panchayat including road restoration works. EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

KWA-JB-GL-6-1881-2022-23

Superintending Engineer
PH Circle, Pathanamthitta

KERALA WATER AUTHORITY e-Tender Notice
Tender No: He T No.113/2022-23/SEC

Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I- KLM SSO1 and for commissioning of Karumali Vadi pumping station balance works EMD : Rs. 500000 Tender fee : Rs. 16540-2978 Last Date for submitting Tender : 10-04-2023 02:00pm Phone : 04724745293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

KWA-JB-GL-6-1892-2022-23

Superintending Engineer
PH Circle, Kollam

KIFS HOUSING FINANCE LIMITED PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE

Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Elitbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.

KIFS HOUSING FINANCE LIMITED
C-902, Lotus Corporate Park, Graham Firth Compound, Western Express Highway, Goregaon (East), Mumbai-400063.
Tel: +91 22 61796400

Date: 21/03/2023

VIP Industries Limited
5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025

NOTICE
Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s). Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775

Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED

Corporate Identification Number: U51496MH2008PLC184997

Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Speciality Chemicals Private Limited" under the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Speciality Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016, Our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.

Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.

Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director
Tel No: 022- 42221111 | Email Id: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta

BASIS OF ALLOTMENT

PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹5,009.55 LAKHS (THE "ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1 : 1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1 : 1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1 : 1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1 : 1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1 : 1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1 : 1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1 : 1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity Shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)
Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and final basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FII/FPis	MFs	NBFCs	OTHs	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)
The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹ 73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalised in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity Shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalised in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before **March 17, 2023** and payment to non-Syndicate brokers has been issued on **March 20, 2023**. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before **March 20, 2023** for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on **March 22, 2023**.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("ROC").

INVESTORS, PLEASE NOTE

These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFINTECH
KFIN TECHNOLOGIES LIMITED
Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana.
Tel: +91 40 6716 2222/ 180034 54001;
E-mail: airward.ris@kfintech.com | Website: www.kfintech.com
Investor grievance e-mail: spil ipo@kfintech.com
Contact person: M Murali Krishna | SEBI Registration No.: INR000000221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited

Sd/-
Hemal Vasantrai Mehta
Managing Director
DIN: 02211121

Date: March 20, 2023

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the ROC on March 16, 2023 and thereafter with the SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited <https://www.bseindia.com/and> on the websites of the BRLM, GreteX Corporate Services Limited at <https://gretexcorporate.com/ipo/investors> should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION

The Corrigendum is with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).

Attention of Investors is drawn
"On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, it will be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."

The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

BID/ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023

BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023

BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 25(3) of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs"), the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalised at ₹ 73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 56,998,400/-.

The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1.6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,20,000	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,600.00	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,000.00	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,800.00	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,000.00	7,80,800	1.06
Total (A)	2,781	72,72,000	53,08,17,600.00	68,62,400	1.06	
6.	Underwriters* (B)	1	4,22,400	3,08,35,200.00	-	0.00
Grand Total (A + B)	2,782	76,94,400	56,16,52,800	68,62,400	1.12	

*Unsubscribed portion of 4,22,400 Equity Shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:

A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.88
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
TOTAL		1,02,57,600	100.00		

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.

1) Allotment to Retail Individual Investors (After Technical Rejections)
The Basis of Allotment to the Retail Individual Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 73.00 per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 42,72,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	42,72,000	100.00	1600	1:1	42,72,000	0

Includes spilled over of 6,20,800 Equity Shares from NIB category.

2) Allotment to Non-Institutional Investors (After Technical Rejections)
The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

FORM G INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESS ACROSS INDIA

(Under Regulation 38A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

RELEVANT PARTICULARS	
1. Name of the Corporate Debtor along with CIN / PAN	Future Supply Chain Solutions Limited CIN: L63030MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jageshwar - Vikhroli Link Road, Jogeshwari East, Mumbai 400069
3. URL of website	https://www.futurechain.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workmen	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futurechain.fsc@gmail.com
9. Eligibility for resolution applicants under section 25(2)(h) of the Code is available at:	Details can be sought by emailing futurechain.fsc@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futurechain.fsc@gmail.com

Date : 20/03/2023
Place: Mumbai
Sd/-
Rajan Rawat
Resolution Professional
In the matter of Future Supply Chain Solutions Limited
AFA Valid Up to 12-12-2023
Address: B-602, Azziano, Rustomjee House, Majwada, Thane West, Mumbai-400061
Correspondence Address: 144, Mittal Court, B Wing, 14th Floor, Nariman Point, Mumbai, Maharashtra, 400021

SALE NOTICE Lanco Babandh Power Limited - (IN LIQUIDATION)

Liquidator: Mr. Sanjay Gupta
Liqudator's Address: E-10A, Kailash Colony, Greater Kailash-I, New Delhi -110048
Email Id: assetsale@saainsoolvency.in, lancobabandh@saainsoolvency.in
Contact No: +91 880065284 - Mr. Puneet Sachdeva and Mr. Raj Kumar

E-AUCTION
Sale of Assets under

ASSAM POWER DISTRIBUTION COMPANY LIMITED
(A Govt. of Assam Public Limited Company)

REQUEST FOR PROPOSAL
RFP Notice No.: CGM [Com & EE]/APDCL/Banking/2022/26 dt. 20-03-2023

APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 from the utility/ trader. The detail is available in APDCL website www.apdcl.org.

Last date for submission is 10-04-2023.
Sd/- Chief General Manager (Com & EE), APDCL
Bijulee Bhawan, Paltanbazar, Guwahati - 1

Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
Tender No: 119/2022-23/KWA/PHC/IVLA/RI-1/(I)-17067/2022

JJM - 5th SSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandalam Thekkkara panchayat including road restoration works. EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00 pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

Superintending Engineer
PH Circle, Pathanamthitta

KWA-JB-GL-6-1881-2022-23

KERALA WATER AUTHORITY e-Tender Notice
Tender No: H-1 No.113/2022-23/SEO

Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I - KLM SSO1 and for commissioning of Karumali Vadi pumping stations balance works EMD : Rs. 500000 Tender fee : Rs. 16540-2978 Last Date for submitting Tender: 10-04-2023 02:00 pm Phone : 04742745293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

Superintending Engineer
PH Circle, Kollam

KWA-JB-GL-6-1892-2022-23

KIFS HOUSING FINANCE LIMITED
PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE

Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Ellisbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.

KIFS HOUSING FINANCE LIMITED
C-902, Lotus Corporate Park, Graham Frith Compound, Western Express Highway, Goregaon (East), Mumbai-400083.
Tel: +91 22 61796400

Date: 21/03/2023

VIP Industries Limited
5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025

NOTICE

Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s).

Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775

Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED

Corporate Identification Number: U51496MH2008PLC184997

Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Speciality Chemicals Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Speciality Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016. Our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.

Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.

Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director
Tel No: 022- 42221111 | Email id: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta

BASIS OF ALLOTMENT

PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUEPRICE") AGGREGATING TO ₹5,009.55 LAKHS (THE "ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor or would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1 : 1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1 : 1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1 : 1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1 : 1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1 : 1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1 : 1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1 : 1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)
Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and firm basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FIs/FPIs	MFs	NBFCs	OTHs	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)
The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹ 73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalized in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalized in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before **March 17, 2023** and payment to non-Syndicate brokers has been issued on **March 20, 2023**. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before **March 20, 2023** for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on **March 22, 2023**.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("RoC").

INVESTORS, PLEASE NOTE
These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFIN TECHNOLOGIES LIMITED
Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana
Tel: +91 40 6716 2222/180034 540011
E-mail: ainward@kfintech.com | Website: www.kfintech.com
Investor grievance e-mail: spil.ip@kfintech.com
Contact person: M Murali Krishna | SEBI Registration No.: INRD00000221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited
Sd/-
Hemal Vasantrai Mehta
Managing Director
DIN: 02211121

Place: Mumbai
Date: March 20, 2023

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the RoC on March 16, 2023 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited at <https://www.bseindia.com/and> on the websites of the BRLM, GreteX Corporate Services Limited at <https://gretelex.com/and> ipo/investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION
The Corrigendum is with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).

Attention of Investors is drawn
"On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, it will be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."
The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

BID/ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023
BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023
BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalized at ₹ 73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 56,998,400/-.

The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1,6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,200.00	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,600.00	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,000.00	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,800.00	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,000.00	7,80,800	1.06
6.	Total (A)	2,781	72,72,000	53,08,17,600.00	68,62,400	1.06
	Underwriters* (B)	1	4,22,400	3,08,35,200.00	-	1.00
	Grand Total (A+B)	2,782	76,94,400	56,16,52,800	68,62,400	1.12

*Unsubscribed portion of 4,22,400 equity shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:
A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.88
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
	TOTAL	1,02,57,600	100.00		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.

1) Allotment to Retail Individual Investors (After Technical Rejections)
The Basis of Allotment to the Retail Individual Investors, who have bid at cut-off price or at or above the Issue Price of ₹ 73.00 per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 42,72,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	42,72,000	100.00	1600	1:1	42,72,000	0

Includes spilled over of 6,20,800 Equity Shares from NB category.

2) Allotment to Non-Institutional Investors (After Technical Rejections)
The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

FORM G
INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESS ACROSS INDIA
(Under Regulation 36A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

RELEVANT PARTICULARS	
1. Name of the Corporate Debtor along with CIN / PAN	Future Supply Chain Solutions Limited CIN: L63300MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jogeshwari- Vikhroli Link Road, Jogeshwari East, Mumbai 400069
3. URL of website	https://www.futuresupplychains.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workmen	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futureSupply.fcb@gmail.com
9. Eligibility for resolution applicants under section 25(2)(h) of the Code is available at:	Details can be sought by emailing futureSupply.fcb@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futureSupply.fcb@gmail.com

Date: 20/03/2023
Place: Mumbai
Sd/-
Rajin Rawat
Resolution Professional
In the matter of Future Supply Chain Solutions Limited
AFA Valid Up to 12-12-2023
Address: B-602, Azziano, Rustumje Urbanis, Majiwada, Thane West, Mumbai- 400601
Correspondence Address: 144, Mittal Court, B Wing, 14th Floor, Nariman Point, Mumbai, Maharashtra, 400021

SALE NOTICE
LANCO BABANDH POWER LIMITED- (IN LIQUIDATION)
Liquidator: Mr. Sanjay Gupta
Liquidator's Address: E-10A, Kailash Colony, Greater Kailash-I, New Delhi-110048
Email ID: assetsale@saainsolvency.in, lancobabandh@saainsolvency.in
Contact No: +91 8800865284 - Mr. Puneet Sachdeva and Mr. Raj Kumar

E-AUCTION
Sale of Assets under Insolvency and Bankruptcy Code, 2016
Date and Time of E-Auction: 19th April, 2023 at 3.00 pm-5.00 pm
(With unlimited extension of 5 minutes each)
Last date of Receiving EMD submission: 17th April, 2023 before 3:00 PM
Last date for Submission of Eligibility Documents by prospective bidder: From 21st March, 2023 to 03rd April, 2023

ASSAM POWER DISTRIBUTION COMPANY LIMITED
 (A Govt. of Assam Public Limited Company)
REQUEST FOR PROPOSAL
 RFP Notice No.: CGM (Com & EE)/APDCL/Banking/2022/26 dt. 20-03-2023
 APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 from the utility/trader. The detail is available in APDCL website www.apdcl.org.
 Last date for submission is 10-04-2023.
 Sd/- Chief General Manager (Com & EE), APDCL
 Bijulee Bhawan, Paltanbazar, Guwahati - 1
 Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
 Tender No: 119/2022-23/KWA/PHC/TVA/RI-1/17067/2022
 JIM -5th SSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandalam Thekkera panchayath including road restoration works. EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in
 KWA-JB-GL-6-1881-2022-23
 Superintending Engineer
 PH Circle, Pathanamthitta

KERALA WATER AUTHORITY e-Tender Notice
 Tender No: He 1 No.113/2022-23/SEC
 Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I- KLM SSO1 and for commissioning of Karumali Vadi pumping stations balance works EMD : Rs. 500000 Tender fee : Rs. 16540-2978 Last Date for submitting Tender: 10-04-2023 02:00pm Phone : 04742745293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in
 KWA-JB-GL-6-1892-2022-23
 Superintending Engineer
 PH Circle, Kollam

KIFS HOUSING FINANCE LIMITED PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE
 Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Ellisbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.
 KIFS HOUSING FINANCE LIMITED
 C-902, Lotus Corporate Park, Graham Firth Compound, Western Express Highway, Goregaon (East), Mumbai-400063.
 Tel: +91 22 61796400
 Date: 21/03/2023

VIP Industries Limited
 5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025
NOTICE
 Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s). Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775
 Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED
 Corporate Identification Number: U51496MH2008PLC184997
 Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Specialty Chemicals Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Specialty Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016. Our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.
 Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.
 Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director
 Tel No: 022-42221111 | Email ID: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta

BASIS OF ALLOTMENT
 PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUEPRICE") AGGREGATING TO ₹5,009.55 LAKHS (THE "ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth.

ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023
BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023
BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 25(3) of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs"), the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalized at ₹ 73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 56,998,400/-.

The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1,6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,200.00	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,600.00	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,000.00	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,800.00	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,000.00	7,80,800	1.06
6.	Total (A)	2,781	72,72,000	53,08,17,600.00	68,62,400	1.06
7.	Underwriters* (B)	1	4,22,400	3,08,35,200.00	-	0.00
	Grand Total (A+B)	2,782	76,94,400	56,16,52,800	68,62,400	1.12

*Unsubscribed portion of 4,22,400 equity shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:
 A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.88
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
	TOTAL	1,02,57,600	100.00		

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.

1) Allotment to Retail Individual Investors (After Technical Rejections)
 The Basis of Allotment to the Retail Individual Investors, who have bid at cut-off price or at or above the Issue Price of ₹ 73.00 per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 42,72,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	42,72,000	100.00	1600	1:1	42,72,000	0

Includes spilled over of 6,20,800 Equity Shares from NIB category.

2) Allotment to Non-Institutional Investors (After Technical Rejections)
 The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1:1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1:1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1:1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1:1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1:1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1:1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1:1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)
 Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and firm basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FIs/FPis	MFs	NBFCs	OTHs	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)
 The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹ 73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalised in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalised in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before March 17, 2023 and payment to non-Syndicate brokers have been issued on March 20, 2023. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before March 20, 2023 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on March 22, 2023.

INVESTORS, PLEASE NOTE
 These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFIN TECHNOLOGIES LIMITED
 Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana
 Tel: +91 40 6716 2222 | 180034 54001;
 E-mail: eisward.ris@kfintech.com | Website: www.kfintech.com
 investor grievance e-mail: spii.ipo@kfintech.com
 Contact person: M Murali Krishna | SEBI Registration No.: INR000000221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited
 Sd/-
Hemal Vasantrai Mehta
 Managing Director
 DIN: 02211121

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the RoC on March 16, 2023 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited at https://www.bsesme.com/ and on the websites of the BRLM, GreteX Corporate Services Limited at https://gretelexcorp.com/ ipo/investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION
 The Corrigendum with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).

Attention of Investors is drawn
 "On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, it will be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."
 The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

FORM G
INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESS ACROSS INDIA
 [Under Regulation 35A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016]

RELEVANT PARTICULARS	
1. Name of the Corporate Debtor along with CIN / PAN	Future Supply Chain Solutions Limited CIN: L63030MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jogeshwari- Vikhroli Link Road, Jogeshwari East, Mumbai 400069
3. URL of website	https://www.futureupplychains.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workmen	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futureupply.lbc@gmail.com
9. Eligibility for resolution applicants under section 25(2)(h) of the Code is available at:	Details can be sought by emailing futureupply.lbc@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futureupply.lbc@gmail.com

Date: 20/03/2023
 Place: Mumbai
 Sd/-
Rajan Rawat
 Resolution Professional
 In the matter of Future Supply Chain Solutions Limited
 AFA Valid Up to 12-12-2023
 Address: B-602, Azziano, Rustomjee Meadows, Thane West, Mumbai-400601
 Correspondence Address: 144, Mital Court, B Wing, 14th Floor, Naaman Point, Mumbai, Maharashtra, 400021

SALE NOTICE
LANCO BABANDH POWER LIMITED- (IN LIQUIDATION)
 Liquidator: Mr. Sanjay Gupta
 Liquidator's Address: E-10A, Kailash Colony, Greater Kailash-1, New Delhi-110048
 Email ID: assetsale1@saainsoolvency.in, lanco.babandh@saainsoolvency.com
 Contact No: +91 8800865284 - Mr. Puneet Sachdeva and Mr. Raj Kumar

E-AUCTION
 Sale of Assets under Insolvency and Bankruptcy Code, 2016
 Date and Time of E-Auction: 19th April, 2023 at 3:00 pm-5:00 pm
 (With unlimited extension of 5 minutes each)
 Last date of Receiving EMD Submission: 17th April, 2023 before 3:00 PM
 Last date for Submission of Eligibility Documents by prospective bidder: From 21st March, 2023 to 03rd April, 2023

Sale of Assets and Properties owned by **Lanco Babandh Power Ltd (In Liquidation)** forming part of Liquidation Estate formed by the Liquidator, appointed by the Hon'ble National Company Law Tribunal, Hyderabad Bench vide order dated 27th November, 2019. The sale will be done by the undersigned through the E-auction platform i.e. M/S National E-Governance Services Ltd (NeSL), having website at: https://nbiid.nesl.co.in/np/liquidn.

Particulars of Asset	Block	Reserve Price (INR)	Initial EMD (INR)	Incremental Value (INR)
Plant and Machinery at Thermal Power Plant of Lanco Babandh Power Ltd at Vihakapattan-Port	A	27,25,000	1,30,000	10,000

Terms and Condition of the E-auction are as under
 1. E-Auction will be conducted on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS" through approved service provider i.e. i.e. NeSL (National E-Governance Services Ltd.)
 2. It is clarified that this invitation purports to invite prospective bidders and does not create any kind of binding obligation on the part of the Liquidator or the Company to effectuate the sale. The Liquidator reserves the right to cancel or modify the process and/or not to accept and/or disqualify any interested party / potential investor / bidder without assigning any reason and without any liability.
 3. The custody of plant and machinery with respect to Block A shall only be given to the successful bidder after release of assets by the port authorities, for which, proceedings are ongoing before Hon'ble NCLT, Hyderabad Bench vide order dated 27th November, 2019. The Liquidator (in the matter of Lanco Babandh Power Limited) vs VPL, Interim CFS Pvt Ltd & Anr. The matter is reserved for orders.

ASSAM POWER DISTRIBUTION COMPANY LIMITED
(A Govt. of Assam Public Limited Company)

REQUEST FOR PROPOSAL
RFP Notice No.: CGM (Com & EE)/APDCL/Banking/2022/26 dt. 20-03-2023

APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 from the utility/ trader. The detail is available in APDCL website www.apdcl.org.

Last date for submission is 10-04-2023.

Sd/- Chief General Manager (Com & EE), APDCL
Bijulee Bhawan, Palantabazar, Guwahati - 1

Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
Tender No: 119/2022-23/KWA/PH/CL/VAI(R-1)/(17-06/2022)

JJM-5th SLSSC Laying distribution system and providing 4182 FHTCs from proposed OHSR in Pandalam Thekkarak panchayath including road restoration works. EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

KWA-JB-GL-6-1881-2022-23

Superintending Engineer
PH Circle, Pathanamthitta

KERALA WATER AUTHORITY e-Tender Notice
Tender No: Re 1 No.113/2022-23/SE/Q

Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I- KLM SS01 and for commissioning of Karumail Vadi pumping stations balance works EMD : Rs. 500000 Tender fee : Rs. 16540+2978 Last Date for submitting Tender : 10-04-2023 02:00pm Phone : 047245293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

KWA-JB-GL-6-1892-2022-23

Superintending Engineer
PH Circle, Kollam

KIFS HOUSING FINANCE LIMITED
PUBLIC NOTICE

SHIFTING OF REGISTERED OFFICE

Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-51, Pariseema Complex, C. G. Road, Ellisbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.

KIFS HOUSING FINANCE LIMITED
C-902, Lotus Corporate Park, Grahm Firth Compound, Western Express Highway, Goregaon (East), Mumbai-400063.
Tel:- +91 22 61796400

Date: 21/03/2023

VIP Industries Limited
5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025

NOTICE

Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s). Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775

Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED

Corporate Identification Number: U51496MH2008PLC184997

Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Specialty Chemicals Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Specialty Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016. Our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further Details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.

Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.

Contact Person: Mr. Hemal Vasantra Mehta, Managing Director
Tel No: 022- 42221111 | Email id: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantra Mehta and Mr. Sachin Vasantra Mehta

BASIS OF ALLOTMENT

PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUEPRICE") AGGREGATING TO ₹5,009.55 LAKHS (THE "ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor or would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth.

The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1 : 1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1 : 1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1 : 1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1 : 1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1 : 1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1 : 1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1 : 1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity Shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)
Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and firm basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FII/FPi	MFs	NBFCs	OTHS	Total
QIB	-	-	-	2,73,600	-	-	2,73,600
							2,48,000
							5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)
The Company in consultation with the BRLMs have allotted 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalized in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity Shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity Shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalized in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before March 17, 2023 and payment to non-Syndicate brokers has been issued on March 20, 2023. In case the same is not received within ten days, investors may contact the Registrar to the issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before March 20, 2023 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on March 22, 2023.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("RoC").

INVESTORS, PLEASE NOTE
These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ Sole applicant. Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFIN TECHNOLOGIES LIMITED
Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana
Tel: +91 40 6716 2222/ 180034 54001;
E-mail: enward.ris@kfintech.com | Website: www.kfintech.com
Investor grievance e-mail: spil ipo@kfintech.com
Contact person: M Murali Krishna | SEBI Registration No.: INF000000221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited
Sd/-
Hemal Vasantra Mehta
Managing Director
DIN: 02211121

Place: Mumbai
Date: March 20, 2023

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the RoC on March 16, 2023 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited at <https://www.bsesme.com> and on the websites of the BRLM, Greteq Corporate Services Limited at <https://greteqcorp.com> / ipo/investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION
The Corrigendum is with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).

Attention of Investors is drawn
"On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, it will be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."
The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized terms used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

BID/ISSUE PERIOD
ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023
BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023
BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs"), the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalized at ₹73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹56,998,400/-.

The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1,6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,200.00	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,600.00	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,000.00	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,800.00	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,000.00	7,80,800	1.06
	Total (A)	2,781	72,72,000	53,08,17,600.00	68,62,400	1.06
6.	Underwriters* (B)	1	4,22,400	3,08,35,200.00	-	0.00
	Grand Total (A+B)	2,782	76,94,400	56,16,52,800	68,62,400	1.12

*Unsubscribed portion of 4,22,400 equity shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:
A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.86
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
	TOTAL	1,02,57,600	100.00		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.

1) Allotment to Retail Individual Investors (After Technical Rejections)

The Basis of Allotment to the Retail Individual Investors, who have bid at cut-off Price or at or above the Issue Price of ₹73.00 per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 42,72,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	42,72,000	100.00	1600	1:1	42,72,000	0

Includes spilled over of 6,20,800 Equity Shares from NIB category.

2) Allotment to Non-Institutional Investors (After Technical Rejections)
The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

FORM G
INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESS ACROSS INDIA
(Under Regulation 36A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

RELEVANT PARTICULARS

1. Name of the Corporate Debtor along with CN / PAN	Future Supply Chain Solutions Limited CIN: L63030MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jogeshwan- Vikhroli Link Road, Jogeshwan East, Mumbai 400069
3. URL of website	https://www.futureupplychains.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workman	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futuresupply.lbc@gmail.com
9. Eligibility for resolution applicants under section 25(2)(b) of the Code is available at:	Details can be sought by emailing futuresupply.lbc@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futuresupply.lbc@gmail.com

Date: 20/03/2023
Place: Mumbai
Sd/-
Rajan Rawat
IBBI Reg. No.: IBBI/PA-02/P-N074/2018-2019/1282
Resolution Professional
In the matter of Future Supply Chain Solutions Limited
AFA Valid Up to 12-12-2023
Address: B-602, Azzano, Rustamjee Urbana, Majiwada, Thane West, Mumbai-400051
Correspondence Address: 144, Mittal Court, B Wing, 14th Floor, Nariman Point, Mumbai, Maharashtra, 400021

SALE NOTICE
LANCO BABANDH POWER LIMITED- (IN LIQUIDATION)
Liquidator: Mr. Sanjay Gupta
Liquidator's Address: E-10A, Kailash Colony, Greater Kailash-I, New Delhi-110048
Email ID: aseel1@aainsoolvency.in, lanco.babandh@aainsoolvency.com<

ASSAM POWER DISTRIBUTION COMPANY LIMITED
(A Govt. of Assam Public Limited Company)

REQUEST FOR PROPOSAL
RFP Notice No.: CGM [Com & EE]/APDCL/Banking/2022/26 dt. 20-03-2023

APDCL is inviting Request for Proposal for Banking of Power during FY year 2023-24 from the utility/ trader. The detail is available in APDCL website www.apdcl.org.

Last date for submission is 10-04-2023.
Sd/- Chief General Manager (Com & EE), APDCL
Bijulee Bhawan, Palitambazar, Guwahati - 1

Please pay your energy bill on time and help us to serve you better!

KERALA WATER AUTHORITY e-Tender Notice
Tender No: 119/2022-23/KWA/PHC/IVLA/RI-1/(16-17/06/2022)
JIM -5th SSSC Laying distribution system and providing 4192 FHTCs from proposed OHSR in Pandalam Thekkera panchayath including road restoration works. EMD : Rs. 500000 Tender fee : Rs. 19518 Last Date for submitting Tender : 03-04-2023 02:00 pm Phone : 04692600162 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

Superintending Engineer
PH Circle, Pathanamthitta

KWA-JB-GL-6-1881-2022-23

KERALA WATER AUTHORITY e-Tender Notice
Tender No: H-1 No.113/2022-23/SEO
Rehabilitation of existing sewerage system, extension of the sewerage systems for Zone A1 Part I-KLM SSO1 and for commissioning of Karumali Vadi pumping stations balance works EMD : Rs. 500000 Tender fee : Rs. 16540-2978 Last Date for submitting Tender: 10-04-2023 02:00pm Phone : 04742745293 Website : www.kwa.kerala.gov.in, www.etenders.kerala.gov.in

Superintending Engineer
PH Circle, Kollam

KWA-JB-GL-6-1892-2022-23

KIFS HOUSING FINANCE LIMITED
PUBLIC NOTICE
SHIFTING OF REGISTERED OFFICE

Notice is hereby given that the KIFS Housing Finance Limited, hereby informs its customers and concerned that its Registered Office is shifted from B-81, Pariseema Complex, C. G. Road, Ellisbridge, Ahmedabad - 380006 to 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 with effect from March 20, 2023. All customers and concerned are requested to take note of the change of address and contact our Registered office at 6th Floor, KIFS Corporate House, Beside Hotel Planet Landmark, Near Ashok Vatika BRTS, ISKON-Ambli Road, Ambli, Ahmedabad, Gujarat - 380058 hereafter.

KIFS HOUSING FINANCE LIMITED
C-902, Lotus Corporate Park, Graham Frith Compound, Western Express Highway, Goregaon (East), Mumbai-400083.
Tel: +91 22 61796400

Date: 21/03/2023

VIP Industries Limited
5th Floor, DGP House, 88C, Old Prabhadevi Road, Mumbai, Maharashtra - 400025

NOTICE

Notice is hereby given that the Certificate(s) for the under mentioned Equity Shares of the Company have been lost and the holder(s) of the said Equity Shares have applied to the Company to issue duplicate share certificate(s).

Any person who has a claim in respect of the said Shares should lodge the same with the Company at its Registered Office within 21 days from this date else the Company will proceed to issue duplicate certificate(s) to the aforesaid applicants without any further intimation. Folio No. 0010930, Name of Shareholders Shuchita Surana & Vipin Surana, No. of shares 500, Distinctive Nos. 513656-514155 Certificate No. 775

Shuchita Surana & Vipin Surana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA

SUDARSHAN PHARMA INDUSTRIES LIMITED

Corporate Identification Number: U51496MH2008PLC184997

Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Speciality Chemicals Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Speciality Chemicals Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the Extra-Ordinary General Meeting held on December 12, 2016. Our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997. For further Details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 147 of this Prospectus.

Registered office: 301, 3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.

Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director
Tel No: 022- 42221111 | Email id: compliance@sudarshanpharma.com

PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta

BASIS OF ALLOTMENT

PUBLIC ISSUE OF 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹73.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹63.00 PER EQUITY SHARE (THE "ISSUEPRICE") AGGREGATING TO ₹5,009.55 LAKHS (THE "ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹251.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 65,18,400 EQUITY SHARES AGGREGATING TO ₹4,758.43 LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10.00 EACH
ANCHOR INVESTOR ISSUE PRICE: ₹73.00 PER EQUITY SHARE
THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE

Risks to Investors:

- There are outstanding legal proceedings involving our Company, our Subsidiary, our Group Entity, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on our business, results of operations and financial condition.
- Our Registered Office and Factory Offices are not owned by us. The same are occupied by us on a lease basis. Disruption of our rights as lessee or termination of the agreements with our lessor or would adversely impact our operations and, consequently, our business.
- We require certain approvals and licenses in the ordinary course of business and are required to comply with certain rules and regulations to operate our business, and the failure to obtain, retain and renew such approvals and licenses or comply with such rules and regulations, and the failure to obtain or retain them in a timely manner or at all may adversely affect our operations.
- There are no long-term supply agreements with our vendors / suppliers.
- The COVID-19 pandemic has had, and is expected to have, a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our business is substantially dependent on our key customers from whom we derive a significant portion of our revenues. The loss of any significant clients may have a material and adverse effect on our business and results of operations.
- Our revenues are dependent upon our meeting specific customer requirements largely on a case-to-case basis. Any failure or limitation on our ability to provide services may detrimentally affect our future growth

applicants. The details of the Basis of Allotment of the said category are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,200	28	70.00	89,600	17.18	3,200	1:1	89,600	-1,79,200
4,800	3	7.50	14,400	2.76	4,800	1:1	14,400	-28,800
6,400	5	12.50	32,000	6.13	6,400	1:1	32,000	-64,000
12,800	1	2.50	12,800	2.45	12,800	1:1	12,800	-25,600
14,400	1	2.50	14,400	2.76	14,400	1:1	14,400	-28,800
16,000	1	2.50	16,000	3.07	16,000	1:1	16,000	-32,000
3,42,400	1	2.50	3,42,400	65.64	3,42,400	1:1	3,42,400	-6,84,800
TOTAL	40	100.00	5,21,600	100.00			5,21,600	-10,43,200

The unsubscribed portion of 6,20,800 Equity Shares spilled over to Retail Portion category and 4,22,400 Equity shares spilled over the Merchant banker Underwriters obligation.

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)
Allotment to QIBs, who have bid at the Issue Price of ₹73.00 per Equity Share or above, has been done on full and firm basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.00 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,21,600 Equity Shares, which were allotted to 2 successful Applicants.

Category	AIF	FI	FIs/FPIs	MFs	NBFCs	OTHs	Total
QIB	-	-	2,73,600	-	-	2,48,000	5,21,600

4) Allotment to Anchor Investors (After Technical Rejections)
The Company in consultation with the BRLMs have allocated 7,80,800 Equity Shares to 2 Anchor Investors (through 2 Anchor Applications) at the Anchor Investor Issue Price of ₹ 73 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion, of the initial Issue size as envisaged at the time of Bid/Offer opening.

Category	MFs	ICs	AIFs	FPI/FIs	Total
Anchor	-	-	-	7,80,800	7,80,800

5) Market Maker's Category (After Technical Rejections): The basis of allotment to Market maker, at the issue price of ₹73 per equity share, was finalized in consultation with BSE Limited. The category was subscribed to 1.00 times. The total no. of shares allotted in this category is 3,44,000 Equity Shares.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
3,44,000	1	100.00	3,44,000	100.00	3,44,000	1:1	3,44,000	0

6) Book Running Lead Manager as Underwriter Obligations (After Technical Rejections): Unsubscribed portion of 4,22,400 Equity shares under the category of Non-Retail Investors brought in by the Book Running Lead Manager Underwriters' obligation at the price of ₹73.00 per Equity share. Book Running Lead Manager, have agreed to fulfill their underwriting obligation of 94.99% of the issue size on their own account and have accordingly subscribed for 4,22,400 Equity shares. The Basis of Allotment for Book Running Lead Manager as Underwriter Category at the price of ₹73.00 per Equity Share, was finalized in consultation with BSE and 4,22,400 Equity Shares were allotted to Book Running Lead Manager.

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
4,22,400	1	100.00	4,22,400	100.00	4,22,400	1:1	4,22,400	0

The Board of Directors of our Company at its meeting held on March 17, 2023 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs has been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before **March 17, 2023** and payment to non-Syndicate brokers has been issued on **March 20, 2023**. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before **March 20, 2023** for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on **March 22, 2023**.

Note: All capitalized terms used and not defined herein shall have the meanings assigned to them in the Prospectus dated March 16, 2023 filed with the Registrar of Companies, Mumbai, Maharashtra ("RoC").

INVESTORS, PLEASE NOTE

These details of the Allotment made has been hosted on the website of Registrar to the Offer, KFIN TECHNOLOGIES LIMITED at www.kfintech.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, Bidders DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application form was submitted by the Bidder and Copy of the Acknowledgment slip received from the Designated intermediary and name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:

KFIN TECHNOLOGIES LIMITED
Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana
Tel: +91 40 6716 2222/ 1800334 540011
E-mail: ainward.nis@kfintech.com | Website: www.kfintech.com
Investor grievance e-mail: spil.ip@kfintech.com
Contact person: M Murali Krishna | SEBI Registration No.: INRO00000221

On behalf of Board of Directors
Sudarshan Pharma Industries Limited
Sd/-
Hemal Vasantrai Mehta
Managing Director
DIN: 02211121

Place: Mumbai
Date: March 20, 2023

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SUDARSHAN PHARMA INDUSTRIES LIMITED.

Disclaimer: Sudarshan Pharma Industries Limited has filed the Prospectus with the RoC on March 16, 2023 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of SME Platform of BSE Limited at www.bseindia.com/and on the websites of the BRLM, GreteX Corporate Services Limited at www.greterx.com/ ipo/investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

ATTENTION

The Corrigendum is with reference to the Prospectus dated March 16, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on March 16, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).

Attention of Investors is drawn
"On Page No. 63 (Sixty Three), wherein Issued Subscribed and Paid-up Share Capital after the issue stated as 2,40,65,897 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Ninety Seven) Equity Shares, it will be read as Issued Subscribed and Paid-up Share Capital after the issue i.e. 2,40,65,887 (Two Crore Forty Lakhs Sixty Five Thousand Eight Hundred And Eighty Seven) Equity Shares."

The above to be read in conjunction with the Prospectus. The information in this CORRIGENDUM supplements the Prospectus and updates the information in the Prospectus as applicable. All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Prospectus.

BID/ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE WAS: WEDNESDAY, MARCH 08, 2023
BID/ISSUE OPENED ON: THURSDAY, MARCH 09, 2023
BID/ISSUE CLOSED ON: TUESDAY, MARCH 14, 2023

The Issue is being made through the Book Building Process. In terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 25(3) of the SEBI ICDR Regulations, as amended, wherein not more than 20% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 24% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 56% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 238 of this Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, March 08, 2023. The Company received 2 applications from 2 anchor investors for 8,24,000 Equity Shares. The Anchor Investor Issue Price was finalized at ₹ 73 per Equity Share. A total of 7,80,800 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 56,998,400/-.

The Issue (excluding Anchor Investors Portion) received 2,782 Applications for 7,694,400 Equity Shares (before technical rejections) resulting in 1,6619 times subscription (including reserved portion of market maker and including Underwriter). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	No. of Valid Applications	No. of Equity Shares applied	Amount (in ₹)	Equity Shares Reserved as per Prospectus	No. of times Subscribed
1.	Retail-Individual Investors	2,733	43,72,800	31,91,79,200.00	36,51,200	1.20
2.	Non-Institutional Investors	43	12,09,600	8,82,97,600.00	15,64,800	0.77
3.	Market Maker	1	3,44,000	2,51,12,000.00	3,44,000	1.00
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	2	5,21,600	3,80,76,800.00	5,21,600	1.00
5.	Anchor Investors	2	8,24,000	6,01,52,000.00	7,80,800	1.06
Total (A)	2,781	72,72,000	53,08,17,600.00	66,62,400	1.06	
6.	Underwriters* (B)	1	4,22,400	3,08,35,200.00	-	0.00
Grand Total (A+B)	2,782	76,94,400	56,16,52,800	66,62,400	1.12	

*Unsubscribed portion of 4,22,400 equity shares brought-in by the Merchant banker Underwriters obligation as given below.

No. of applications Processed - Book Running Lead Manager	Shares Applied	Shares available for allotment Lead Manager under obligation	No. of times subscribed
1	4,22,400	4,22,400	1.00

Final Demand:

A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1.	71	56,000	0.55	56,000	0.55
2.	72	33,600	0.33	89,600	0.88
3.	73	45,71,200	44.56	46,60,800	45.44
4.	CUTOFF	55,96,800	54.56	1,02,57,600	100.00
TOTAL	1,02,57,600	100.00			

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on March 17, 2023.

1) Allotment to Retail Individual Investors (After Technical Rejections)
The Basis of Allotment to the Retail Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of ₹ 73.00 per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 1.00 times. The total number of Equity Shares Allotted in this category is 42,72,000 Equity Shares to 2,670 successful applicants. The details of the Basis of Allotment of the said category is as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	Surplus / Deficit
1600	2,670	100.00	42,72,000	100.00	1600	1:1	42,72,000	0

Includes spilled over of 6,20,800 Equity Shares from NIB category

2) Allotment to Non-Institutional Investors (After Technical Rejections)
The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹73.00 per Equity Share or above, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.33 times. The total number of Equity Shares Allotted in this category is 5,21,600 Equity Shares to 40 successful

FORM G INVITATION FOR EXPRESSION OF INTEREST FOR FUTURE SUPPLY CHAIN SOLUTIONS LIMITED OPERATING IN LOGISTICS BUSINESSES ACROSS INDIA

(Under Regulation 36A(1) of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

RELEVANT PARTICULARS	
1. Name of the Corporate Debtor along with CIN / PAN	Future Supply Chain Solutions Limited CIN: L63300MH2006PLC160376
2. Address of the registered office	Knowledge House, Shyam Nagar, Jogeshwari- Vikhroli Link Road, Jogeswari East, Mumbai 400069
3. URL of website	https://www.futureupplychains.com/
4. Details of place where majority of fixed assets are located	Located across India
5. Installed capacity of main products/services	NA
6. Quantity and value of main products/ services sold in last financial year	Rs. 60,875.61 Lakhs
7. Number of employees / workmen	2 (Two)
8. Further details including last available financial statements (with schedules) of two years, lists of creditors, relevant dates for subsequent events of the process are available at:	Details can be sought by emailing futureupply.fsc@gmail.com
9. Eligibility for resolution applicants under section 25(2)(h) of the Code is available at:	Details can be sought by emailing futureupply.fsc@gmail.com
10. Last date for receipt of expression of interest	04 th April, 2023
11. Date of issue of provisional list of prospective resolution applicants	14 th April, 2023
12. Last date for submission of objections to provisional list	19 th April, 2023
13. Process email id to submit EOI	futureupply.fsc@gmail.com

Date: 20/03/2023
Place: Mumbai

Sd/-
Rajin Rawat
Resolution Professional
In the matter of Future Supply Chain Solutions Limited
AFA Valid Up to 12-12-2023
Address: B-602, Azziano, Rustomjee Urbania, Majajuda, Thane West, Mumbai- 400061
Correspondence Address: 144, Mittal Court, B Wing, 14th Floor, Nariman Point, Mumbai, Maharashtra, 400021

SALE NOTICE Lanco Babandh Power Limited- (IN LIQUIDATION)

Liquidator: Mr. Sanjay Gupta

Liquidator's Address: E-10A, Kailash Colony, Greater Kailash-1, New Delhi-110048
Email ID: assetale1@saainsoolvency.in, lancobabandh@saainsoolvency.in
Contact No.: +91 8800865284 - Mr. Puneet Sachdeva and Mr. Raj Kumar

E-AUCTION
Sale of Assets under Insolvency and Bankruptcy Code, 2016
Date and Time of E-Auction: 19th April, 2023 at 3:00 pm-5:00 pm (With unlimited extension of 5 minutes each)
Last date of Receiving EMD submission: 17th April, 2023 before 3:00 PM
Last date for Submission of Eligibility Documents by prospective bidder: From 21st March, 2023 to 03rd April, 2023

Sale of Assets and Properties owned by Lanco Bab